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ABSTRACT 
 
SUZANNE BELINSON: Association of Reproductive History with Human  
Papillomavirus and Cervical Intraepithelial Neoplasia Severity  
(Under the direction of Katherine Hartmann) 
 
Our objective was to uncover potential links between Human Papillomavirus infection, 
common reproductive outcomes and high-grade cervical pre-cancer. We evaluated common 
reproductive risk factors, by varied stratifications of histologic grade, among 2,055 women 
positive and 6,657 women negative for Human Papillomavirus (HPV), who were enrolled in the 
Shanxi Province Cervical Cancer Screening Study II. Logistic regression was used to generate 
odds ratios and their corresponding 95% confidence intervals.  
Risk-factor profiles diverged for Cervical Intraepithelial Neoplasia (CIN) II compared to CIN 
III, but were broadly similar for CIN II compared to CIN I. An increased risk of CIN III versus 
CIN II was seen for higher gravidity (≥ 3 pregnancies) [odds ratio (OR)=1.6 (95% confidence 
interval [CI]: 1.0, 2.6)] and sexual intercourse within four months of childbirth [OR=2.0 (1.3, 
3.2)]. Risks associated with reproductive factors appeared comparable for CIN II and CIN I, 
except an inverse association observed for sexual intercourse within four months of childbirth for 
CIN II versus CIN I [OR= 0.64 (0.42, 0.97)]. If CIN III and CIN II are biologically similar, risk-
factor profiles would be expected to be more similar between CIN III and CIN II. Instead, risk 
factor profiles between CIN II and CIN I were more similar.  
Utilizing these results, we investigated a broader spectrum of reproductive risk factors for 
CIN III versus ≤ CIN II. Higher gravidity (≥ 3 pregnancies) was associated with higher risk of 
CIN III versus ≤ CIN II [OR=1.5 (1.0, 2.1)], as was intercourse within four months of childbirth 
[OR=1.7 (1.2, 2.3)], and age. It is biologically plausible that elevated levels of hormones during 
pregnancy or immediately postpartum may act as promoters in cervical carcinogenesis, aiding the 
  iv
progression of cervical disease. These results add to the accumulating evidence that CIN II may 
be biologically more similar to CIN I than to CIN III, and that reproductive co-factors play an 
important role in the progression of HPV to high-grade pre-cancer. These results can provide 
impetus for investigators with prospective data to follow-up women with CIN II, and to analyze 
risk factors by histological grade.   
  v
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
The five years of work needed to complete this dissertation have left me permanently 
changed and strengthened. The completion of the work would not have been possible without a 
network of support. I am most grateful for my parents, who taught me that anything is attainable, 
and who are always there to catch me when I fall. This project would not have come to 
completion without the dedication of my committee; they worked hard and fast to meet my 
deadlines. Jamie you are my heart; your support and encouragement was essential. You replenish 
me when I feel there is nothing left. To my daughter Madeline, you are why I do what I do. I hope 
that I make you all proud.  
  vi
 
 
 
 
 
 
TABLE OF CONTENTS 
 
Page 
LIST OF TABLES ..........................................................................................................................ix 
LIST OF FIGURES..........................................................................................................................x 
LIST OF ABBREVIATIONS .........................................................................................................xi 
 
Chapter 
 
I. REVIEW OF THE LITERATURE......................................................................................1 
A. Conceptual Framework .......................................................................................................1 
B. Background and Significance..............................................................................................2 
1. Human Papillomavirus, Invasive Cervical Cancer .........................................................2 
2. Progression from HPV Infection to CIN III....................................................................3 
3. HPV Cofactors ................................................................................................................4 
4. Parity and Cervical Cancer .............................................................................................5 
a. Potential Biologic Mechanisms for the Effect of Parity on Cervical  
Cancer Development..................................................................................................5 
5. China   ............................................................................................................................6 
a. Cervical Cancer Incidence, Mortality, and Prevention in China ................................7 
C. Summary .............................................................................................................................8 
II. SPECIFIC AIMS................................................................................................................10 
A. Specific Aims and Hypotheses..........................................................................................10 
III. METHODS ........................................................................................................................11 
A. Study Overview.................................................................................................................11 
B. Design................................................................................................................................11 
  vii
1. Study Population ...........................................................................................................11 
2. Methods for the Study...................................................................................................14 
a. Classification of the Exposure ..................................................................................14 
b. Classification of the Outcome ..................................................................................15 
c. Comparison Group Selection....................................................................................15 
3. Data Management .........................................................................................................16 
4. Data Analysis ................................................................................................................16 
a. Specific Aim 1 ..........................................................................................................16 
b. Specific Aim 2 ..........................................................................................................17 
c. Power Calculation.....................................................................................................18 
IV. RESULTS ..........................................................................................................................20 
A. Manuscript 1: Risk factors for Cervical Intra-epithelia Neoplasia II  
seem more similar to grade I than grade II........................................................................20 
1. Introduction...................................................................................................................20 
2. Materials and Methods..................................................................................................21 
3. Results ..........................................................................................................................23 
4. Discussion .....................................................................................................................25 
5. Tables  ..........................................................................................................................29 
6. Figures...........................................................................................................................35 
B. Manuscript 2: Reproductive Risk Factors for Human Papillomavirus 
Infection and Cervical Intra-epithelial Neoplasia III in Chinese  
SPOCCS II study...............................................................................................................37 
1. Introduction...................................................................................................................37 
2. Materials and Methods..................................................................................................38 
3. Results ..........................................................................................................................40 
4. Discussion .....................................................................................................................42 
5. Tables  ..........................................................................................................................48 
6. Figures...........................................................................................................................53 
  viii
V. CONCLUSIONS................................................................................................................56 
A. Summary ...........................................................................................................................56 
B. Study Limitations ..............................................................................................................56 
C. Study Strengths..................................................................................................................57 
D. Future Directions...............................................................................................................58 
 
APPENDICES................................................................................................................................59 
A. Variables Available for Analysis with their Original Coding in the  
SPOCCS II Dataset ...........................................................................................................60 
B. Questionnaire from the SPOCCS II study.........................................................................64 
 
REFERENCES...............................................................................................................................72 
 
 
 
 
 
  ix
LIST OF TABLES 
 
 
Table                            Page 
Table 1. Estimated Cervical Cancer Incidence and Mortality in Yangchen  
County Shanxi Province, China (1/100,000). ....................................................................8 
Table 2. Sensitivity and Specificity of Screening Tests in SPOCCS II..........................................12 
Table 3. Demographics and Reproductive Factors for 2,055 HPV Positive  
and 6,657 HPV Negative Women in the SPOCCS II Study,  
Stratified by Final Histology............................................................................................13 
Table 4. Power to Detect Associations between Number of Pregnancies and  
CIN III vs. ≤ CIN II with 187 Cases................................................................................18 
Table 5. Selected Characteristics of Study Participants among 2,055 HPV  
DNA Positive Women in the SPOCCS II Study, Stratified by  
Histology..........................................................................................................................29 
Table 6. Age-adjusted Odds Ratios for Selected Characteristics among  
HPV DNA Positive Women in the SPOCCS II Study, Comparisons  
by Histology.....................................................................................................................30 
Table 7. Odds Ratios for Selected Characteristics among Women in the SPOCCS II 
Study, Comparisons by Histology. ..................................................................................33 
Table 8. Selected Characteristics of Study Participants among 2,055 HPV  
DNA Positive 6,657 HPV Negative Women in the SPOCCS II  
Study, Stratified by Histological Diagnosis.....................................................................48 
Table 9. Crude and Age-Adjusted Odds Ratios for Selected Reproductive                    
Characteristics among 2,055 HPV DNA positive Women and  
6,657 HPV Negative Women in the SPOCCS II Study...................................................49 
Table 10. Multivariate Odds Rations for Intercourse within Four Months of                     
Childbirth among 8,712 Women in the SPOCCS II Study..............................................52 
 
 
 
 
  x
LIST OF FIGURES 
 
 
Figure                               Page 
Figure 1. Map of China with Shanxi Province Highlighted .............................................................8 
Figure 2. Multivariate Odds Ratios and 95% Confidence Intervals for Selected  
Factors for CIN III vs. CIN II among Women in the SPOCCS II Trial ..........................35 
Figure 3. Multivariate Odds Ratios and 95% Confidence Intervals for Selected  
Factors for CIN II vs. CIN I among Women in the SPOCCS II Trial .............................36 
Figure 4. Causal Diagram for the Relationship between HPV infection,  
Reproductive Factors and the Risk of CIN III. ................................................................53 
Figure 5. Multivariate Odds Ratios and 95% Confidence Intervals for Selected  
Reproductive Risk Factors for CIN III vs. ≤CIN II among Women  
Enrolled in the SPOCCS II trial.......................................................................................54 
Figure 6. Multivariate Odds Ratios and 95% Confidence Intervals for Selected  
Reproductive Risk Factors for CIN I/HPV Positive vs. HPV Negative  
Women Enrolled in the SPOCCS II trial .........................................................................55 
 
 
 
 
   
  xi
LIST OF ABBREVIATIONS 
 
 
CI   confidence interval 
CICAMS Cancer Institute Hospital, Academy of Medical Sciences  
CIN  cervical intraepithelial neoplasia 
DNA  deoxyribonucleic acid 
ECC  endocervical curettage 
HPV  human papillomavirus 
IARC  International Agency for Research on Cancer 
IUD  intrauterine device 
mRNA   messenger ribonucleic acid 
NCI  National Cancer Institute  
OC  oral contraceptive 
OR  odds ratio 
PCR  polymerase chain reaction 
SPOCCS II Shanxi Province Cervical Cancer Screening Study II  
STD  sexually transmitted disease 
TFR  total fertility rate  
  xii
I. INTRODUCTION 
 
 
CHAPTER I 
 
REVIEW OF THE LITERATURE 
 
A. Conceptual Framework 
Human Papillomavirus (HPV) is a common sexually-transmitted infection and the central 
cause of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. Dysplastic 
changes, termed CIN, are classified into three grades, CIN I, CIN II and CIN III, based on 
increasing degrees of cellular change and disorganization. Currently, a two-tiered histological 
grouping has been adopted [1] (CIN I, CIN II/III) to reflect putative differences in the natural 
history between CIN I (lower probability of progressing) and CIN II/III (a dysplastic process 
with greater likelihood for progression to cancer) [1]. It has been hypothesized that a proportion 
of CIN II lesions may be more biologically similar to CIN I than to CIN III [2]. If confirmed, 
future treatment guidelines for women, especially young women, with CIN II diagnoses may 
need revision.   
Infection with oncogenic (high-risk) HPV types alone is not sufficient for cervical 
carcinogenesis. Thus, other exogenous and endogenous factors act in conjunction with oncogenic 
HPV infection to influence the progression from infection to invasive cancer [3]. Identification of 
these HPV co-factors within a group of HPV-infected women can help identify those women at 
the highest risk for progression to CIN III and invasive cervical cancer.  
Parity was one of the earliest risk factors associated with cervical cancer risk [4].  In recent 
studies, the relative risks of cervical cancer among women who have had five or more births have 
ranged from 3.8 (squamous cell carcinoma) [5] to 4.4 [6], compared with nulliparous women or 
5.1 compared with nulliparous or primiparous women [7]. The means by which parity influences 
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progression to cervical cancer is not entirely clear. Hypotheses include: the maintenance of the 
transformation zone, [5] elevated levels of circulating hormones [8], immunosuppression caused 
by pregnancy [9] and cervical trauma related to vaginal delivery [10]. Further research is thus 
needed to investigate mechanisms by which parity may influence the risk of cervical 
carcinogenesis. 
In China, invasive cervical cancer is the seventh leading cause of cancer-related deaths in 
women, with an estimated incidence rate of 5.2/100,000 women among those reporting. As a 
comparison, in 2002 the age-adjusted incidence rate for cervical cancer was 8.7/100,000 for all 
races in the United States [11, 12]. In some provinces of China, such as the Shanxi province in 
the Northeast of the country, the risk of invasive cervical cancer is estimated to be higher at 
14.5/100,000 women. Due to the one child policy in China, on average women have fewer 
children than in other less-developed nations, particularly in Chinese urban centers. In the 
countryside there are more pregnancies and more births than in Chinese urban centers. In one 
study in Xiangyuan County, Shanxi Province, China where the estimated invasive cervical cancer 
incidence rate is estimated to  be 40.7/100,000 women [13], the mean number of pregnancies for 
women enrolled in a cross sectional study of cervical cancer screening was 3.05 with a range of 
0-13 births [14].  
 
B. Background and Significance 
1. Human Papillomavirus, Invasive Cervical Cancer 
High-risk HPV types have been clearly established as the central cause of invasive cervical 
cancer and its related precursors [15]. A study conducted in 22 countries found that the presence 
of high-risk HPV types is nearly universal in invasive cervical cancer (99.6%) [16]. A case-
control study in nine countries using highly-sensitive polymerase chain reaction (PCR)-based 
primers found that HPV types 16 and 18 alone are associated with 60-70% of invasive cervical 
cancer cases [17]. A recent review similarly found that the most common HPV types in 10,058 
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squamous invasive cervical cancer cases were, in order of decreasing prevalence, HPV 16 (46-
63%), 18 (10-14%), 45 (2-8%), 31 (2-7%), 33 (3-5%), 58, 52, 35, 59, and 56 in all regions except 
Asia where HPV types 58 (6%) and 52 (4%) were relatively more common [18, 19]. In a large 
series of 1,518 women aged 15-72 years from a routine care setting in France, 44.0% (150/338) 
of young women (aged 15-30 years) were classified as HPV high-risk positive by Hybrid Capture 
II [20]. It is estimated that high-risk HPV infection is immunologically cleared in most women 
within 12 to 24 months [21-23], although some studies report clearance times that may be slightly 
shorter. Some women who do not clear their high-risk HPV infection progress to develop CIN III 
[24], and of those it is estimated that approximately one-third of women with CIN III will 
progress to develop invasive cervical cancer if untreated [25]. 
The major steps in cervical cancer carcinogenesis are infection with HPV, persistence of 
HPV infection over time, and progression from infection to pre-cancer and invasion [26]. The p53 
protein, a tumor suppressor gene, prevents cell growth in the presence of cell damage. HPV 
oncogenic proteins E6 and E7 can both inhibit p53, thus leading to carcinogenesis. Some women, 
who do not clear their HPV infection, may develop persistent infections, and thus have an 
increased risk of progression to higher grades of CIN. Low-grade lesions (CIN I) may be caused 
by low or high-risk HPV infections [27]. In contrast, high-grade lesions (CIN III) are almost 
always associated with high-risk HPV types, are characteristic of E6 and E7 expression, and often 
show integration of the HPV viral genome into the host cell [28]. It is likely that uncontrolled 
E6/E7 expression is a phenomenon that distinguishes the process of cell transformation from a 
productive viral infection [2]. E6/E7 messenger ribonucleic acid (mRNA) has been found to be 
associated with high-grade cervical pre-cancer and cancer [29], although further prospective 
studies are indicated. 
2. Progression from HPV infection to CIN III 
Although CIN was initially described as a continuum of histological changes (all of which 
were considered true precursors of invasive disease if untreated [27]), our understanding of the 
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natural history of cervical neoplasia has since been revised [27, 30] to acknowledge that CIN does 
not inevitably progress through each higher grade of CIN to cancer. When dysplasia progresses, it 
is thought to be orderly, i.e. not “skipping” from lower grades to cancer. However, progression 
between some levels, for instance from CIN I to CIN II, is the exception rather than the rule. 
Consequently, the classification of cervical cancer precursors by histology may need revision to 
more accurately reflect natural history of disease progression and to better inform clinical 
decision making [27]. Currently, a two-tiered histological grouping has been adopted [1] (CIN I, 
CIN II/III) to reflect putative differences in the natural history between CIN I (lower probability 
of progressing) and CIN II/III (a dysplastic process with a greater likelihood of progression to 
cancer) [1].  
Recent research suggests CIN II may not be a discrete histological grade that can be reliably 
classified, but instead an overlap between CIN I (a non-neoplastic HPV infection) and CIN III (a 
neoplastic cervical cancer precursor) [2, 31]. It has been hypothesized that a proportion of CIN II 
lesions are biologically similar to CIN I and have greater probability of regressing over time, 
while other CIN II lesions are more characteristic of CIN III lesions [2]. Limited by study size, 
few studies have been able to complete the analyses required to compare risk factors by 
histological grade.  
3. HPV Cofactors 
While HPV infection is necessary, it is not sufficient to cause invasive cervical cancer; other 
factors in conjunction with HPV infection lead to persistent HPV infection and progression to 
invasive cervical cancer. Cofactors can be divided into three categories: 1) environmental or 
exogenous factors, including cervical trauma, diet, oral contraceptive (OC) use, smoking, co-
infection with HIV and other sexually transmitted agents; 2) HPV viral cofactors such as 
infection with specific types, viral load and viral integration; 3) host cofactors including genetic 
factors and other host factors related to the host immune response. The most well-established of 
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these cofactors are multiparity, smoking, young age at first intercourse and long term oral 
contraceptive use [3].  
4. Parity and Cervical Cancer 
Parity has consistently been identified as a risk factor for cervical cancer development. Since 
multiparity is still common in many less-developed countries, the contribution of parity in the 
aetiology of cervical cancer development has relevant public health implications [32, 33]. The 
magnitude of the effect of parity has been reported with relative risk estimates ranging from null 
or close to null values [6, 34-40] to 4.4 for five pregnancies compared with nulliparous women 
[6]. In the International Agency for Research on Cancer (IARC) multicenter study, an odds ratio 
(OR) of 3.8 was found for seven pregnancies when compared with nulliparous women or 2.3 
when compared with women who had one or two full-term pregnancies [5]. In Latin America, a 
relative risk of 5.1 was found for women with 14 or more pregnancies compared with nulliparous 
or primiparous women [7]. Most recently, the International Collaboration of Epidemiological 
Studies of Cervical Cancer published a report stating that after controlling for age at first full-
term birth, the relative risk for invasive cervical carcinoma among parous women was 1.76 (95% 
confidence interval [CI]: 1.53-2.02) for ≥ 7 full term pregnancies compared to women with 1-2 
full term pregnancies [15]. This study reanalyzed the data of 16,563 women with cervical 
carcinoma and 33,542 controls from 25 epidemiologic studies. While certainly the largest 
analysis to date, the questions of what mechanism is responsible for the association between 
parity and cervical cancer and at which stage of carcinogenesis parity affects risk remain 
unanswered. 
a. Potential Biologic Mechanisms for the Effect of Parity on Cervical Cancer Development  
There are many possible explanations of the associations seen between parity and cervical 
cancer. Pregnancy may increase the risk of cervical cancer due to the fact that pregnancy 
maintains the transformation zone on the ectocervical region for the full period of the pregnancy, 
leaving the women at greater risk of HPV infection. The number of metaplastic cells in the 
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transformation zone have been shown to increase during pregnancy [5]. These cells are most 
susceptible to HPV infection in this immature phase of development [35]. In a woman who has 
experienced multiple pregnancies, the metaplastic transformation zone will have repeatedly been 
exposed to carcinogenetic agents (i.e. HPV infection). It is this repeated exposure experienced 
over multiple pregnancies that may intensify the actions of carcinogenic infectious agents causing 
an increased risk for cervical cancer [41].  During pregnancy, there are high concentrations of 
circulating oestrogen and progesterone hormones. There is some epidemiologic evidence for a 
role of endogenous hormones in cervical carcinogenesis [8], and several laboratory studies of 
cervical cell lines and HPV-16 transgenic mice [42-46]; however, a case-control study of 
endogenous hormones and cervical cancer found no evidence that plasma levels of sex hormones 
have an important role on the risk of cervical cancer in HPV infected women [40]. An additional 
explanation for the role of hormones during pregnancy may be that they could favor, or accelerate 
cervical carcinogenesis with a mechanism similar to that put forward to explain the increased risk 
of cervical cancer among oral contraceptive users [47, 48]. The data consistently points to oral 
contraceptives promoting some step in the process of cervical carcinogenesis rather than having a 
role in facilitation of infection or persistence [49]. Pregnancy induced immunosuppression 
however may favor the infection or aid in the oncogenic properties of HPV [9]. 
The mechanism may not be related to pregnancy per se but cervical inflammation and trauma 
during delivery. In the IARC multicenter study women who reported cesarean but not vaginal 
deliveries had an odds ratio of 0.98 (95% CI: 0.36, 2.7) when compared to nulliparous women, 
and parous women who reported only cesarean deliveries showed a decreased risk compared with 
women who reported vaginal deliveries only, but the 95% CI was broad (0.1, 1.1) due to the 
rarity of cesarean delivery in the study [5]. 
5. China  
China has the largest population in the world (1.2 billion people; approximately 300 million 
women of reproductive age) and the largest number of invasive cervical cancer cases in the world 
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[50]. Although a one-child policy was introduced in China in 1979, the total fertility rate (TFR) 
never fell below a 2.5 child-per-woman average in rural areas, although it dropped to about 1.2 in 
urban areas. By the mid-1980s, less than one-fifth of all eligible married couples had signed the 
one-child certificate -- a contract which granted couples and their child economic and educational 
advantages in return for promising not to have more than one child. Throughout the 1980s, nearly 
half of all reported births were second, third, or higher order births. Various surveys suggested 
that the desire to have at least two children remains strong among Chinese couples. In the Shanxi 
Province Cervical Cancer Screening Study II (SPOCCS II), a study of 8,079 women in the Shanxi 
province of China, this trend continued with women reporting a mean of 3.05 pregnancies (0-13) 
and a mean of 2.26 live births (0-8) [14].  
Invasive cervical cancer is the second most common cancer in women worldwide and the 
leading cause of cancer mortality in women from the developing world [32]. Of the estimated 600 
women that die each day of cervical cancer, 80% are from the developing world where access to 
cervical cancer screening and therapeutic interventions is limited [32, 51].  In China, over 
100,000 cases of invasive cervical cancer are diagnosed each year, representing over one quarter 
of the cervical cancer cases worldwide [13]. Each year approximately 20,000 women in China die 
of invasive cervical disease [13].  
a.  Cervical Cancer Incidence, Mortality, and Prevention in China 
Cervical cancer mortality rates in Chinese women declined from 10.7/100,000 women in the 
1970s to 3.9/100,000 women in the 1990s due to limited screening in large cities [13]. However, 
with more than 300 million women of reproductive age (15-49 years) in China, there are wide 
regional variations in the documented mortality rates of invasive cervical cancer. Two provinces 
in China (Shanxi and Gansu) have some of the highest reported cervical cancer mortality rates in 
the world (See Figure 1). These invasive cervical cancer mortality rates, standardized to the world 
population, are 40.7/100,000 (Yangcheng, Shanxi Province) and 42.0/100,000 women (Wudu, 
Gansu Province) [13].  
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Table 1. Estimated cervical cancer incidence and mortality in Yangcheng County, Shanxi     
        Province (1/100,000 women) [52] 
 
Age (years) 30-
34 
35-
39 
40-
44 
45-
49 
50-
54 
55-
59 
60-
64 
65-
69 
70-
74 
Total
Incidence per 
100,000 women 
32.6 136.1 234.2 484.5 249.4 298 232.4 174 94.9 132.1
Mortality per 
100,000 women 
3.1 24.4 52.3 141.9 153.2 176.1 146 87 113.9 52.1 
 
Figure 1. Map of China with Shanxi Province Highlighted 
 
C. Summary 
Infection with oncogenic HPV is common. HPV may cause histologic changes which will 
regress over time or progress to cervical cancer if untreated. Dysplastic changes are categorized 
into a two-tiered system CIN I (lesions with a low probability of progression) and CIN II/CIN III 
 
Estimated Cervical Cancer 
Incidence 14.5/100,000 women 
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(lesions with a higher likelihood for progression). Recently, this classification has come under 
reconsideration as studies show CIN II may behave more like CIN I than CIN III.  
Determining whose HPV infection will progress to cervical cancer is one of the unanswered 
questions in the field. Part of this answer may lie in the study of risk-factor profiles. The 
identification of risk factors associated with HPV infection and each subsequent stage of cervical 
abnormality may offer clues. 
Over 100,000 cases of cervical cancer are diagnosed each year in China, representing over 
one quarter of the worldwide cervical cancer incidence. Data from a large study of Chinese 
women offers an opportunity to look at reproductive risk factors for HPV infection and CIN. 
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II.  
III. BACKGR
CHAPTER II 
 
SPECIFIC AIMS 
 
A. Specific Aims and Hypotheses 
The aims of this study were: 
Specific Aim 1:  To determine if CIN II lesions are epidemiologically more similar to CIN I or 
CIN III lesions in terms of risk predictors, among women enrolled in the SPOCCS II study. 
 
Hypothesis: CIN II may be differentially misclassified when grouped with CIN III. By 
investigating the risk factor profiles of CIN II compared to CIN I and CIN III, we can determine 
where they are similar and where they diverge. We believed CIN II would show more similarities 
with CIN I than with CIN III.   
 
Specific Aim 2:  To describe established reproductive cofactors on the risk of CIN III compared 
to those for CIN I/HPV, among women in the SPOCCS II study. 
 
Hypothesis: Histological diagnosis can act as a marker for disease progression. By investigating 
the cofactor profiles between women at various stages of cervical disease in a cross-sectional 
study, it may be possible to determine why some women progress and others do not. We believed 
that parity would be a significant predictor of who progresses and who does not. 
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RATIONALE AND SPECIFIC AIS 
 
CHAPTER III 
 
METHODS 
 
A. Study Overview 
We conducted a research study to: 
1)  Determine if CIN II lesions are epidemiologically more similar to CIN I or CIN III 
lesions in terms of risk predictors, among women enrolled in the SPOCCS II study. 
2) Describe established reproductive cofactors on the risk of CIN III compared to those for 
CIN I/HPV, among women in the SPOCCS II study. 
Many studies have highlighted the role of possible cofactors, like parity, in cervical 
carcinogenesis [49, 53-63]. Most of these studies accounted for HPV infection through statistical 
adjustments.  
Using a cross-sectional study design, we identified risk-factor profiles for HPV infection and 
CIN. Models were restricted to HPV positive women to reduce confounding by HPV infection. 
As a sensitivity analysis, HPV negative women were added and HPV infection status was 
adjusted for in the models. Odds ratios and 95% confidence intervals were generated. 
B. Design 
1. Study Population 
The current analyses used data collected in the Shanxi Province Cervical Cancer Screening 
Study II. These analyses add to the body of information already gained from this study.
Between May 2001 and June 2002, the SPOCCS II cervical cancer screening study was 
conducted in Yangcheng and Xiangyuan counties, Central China, as previously described [14]. In 
brief, women aged 35 to 50 years were invited to participate in a cross-sectional, cervical cancer 
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collaborative project between the Cancer Institute of the Chinese Academy of Medical Sciences 
in Beijing, China and the Cleveland Clinic Foundation in Cleveland, Ohio. A cluster-sampling 
frame was used, where communes within each county were the units for the clusters. Eligibility 
criteria included being a resident of one of 15 county communes, non-pregnant, having an intact 
uterus, no history of pelvic irradiation or cervical cancer, and no screening within the last five 
years. Of a total of 9,034 women attending the Xiangyuan Women’s and Children’s Clinic and 
the Yangcheng Cancer Hospital, 8,798 women (97%) met study eligibility criteria.  SPOCCS II 
enrolled 8,497 women aged 27-56 years; these women had a self-collected test for HPV 
detection, a physician-collected test of cervical exfoliated cells for HPV, and provided cervical 
samples for liquid-based cytology [14]. Sensitivities and specificities of these screening tests are 
presented in Table 2 [14]. The study aimed to increase the sensitivity of the self-test to detect 
high-grade disease by obtaining the specimen with a conical shaped brush (HC Cervical 
Sampler®, Digene, Inc. Gaithersburg, Maryland) versus a Dacron swab (used in SPOCCS I), and 
instructing the women to insert the brush high (6 to 7 cm) into the vagina [64].  
 
Table 2.  Sensitivity and Specificity of Screening Tests in SPOCCS II.  
 
Screening Test 
Biopsy Result 
≥CIN II   <CIN II 
Sensitivity %  
(95% CI) 
Specificity %  
(95% CI) 
Liquid based Cytology  ≥ LSIL  
      Abnormal 
      Normal 
 
294            555 
    81         7,567
 
78.4 
(74.3, 82.5) 
 
93.2 
(92.6, 93.8) 
Liquid based Cytology ≥ HSIL 
       Abnormal 
       Normal 
 
331         1,523 
44          6,599
 
88.3 
(85.0, 91.6) 
 
81.2 
(80.4, 82.0) 
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Self-collected HPV 
      Abnormal 
      Normal 
 
328          1,850 
47          6,272
 
87.5 
(84.2, 90.8) 
 
77.2 
(76.2, 78.2) 
Physician-collected HPV 
      Abnormal 
      Normal 
 
363          1,652 
12          6,470
 
96.8 
(95.0, 98.6) 
 
79.7 
(78.9, 80.5) 
CIN=cervical intraepithelial neoplasia, LSIL=low grade squamous intraepithelial lesion,  
HSIL=high grade squamous intraepithelial lesion, HPV=high-risk human papillomavirus detected 
by Hybrid Capture II®, CI=Confidence Interval. Positive HPV test is defined at 1.0 picograms 
(pg). 
 
Of 8,497 women, there were 7,781 women with negative biopsies, 341 with the most 
abnormal biopsy showing CIN I, 173 with CIN II, 181 with CIN III, and 21 with invasive cancer. 
Therefore, 375 of 8,497 (4.4%) had ≥CIN II. Table 3 contains data on reproductive factors from 
SPOCCS II. 
 
Table 3. Demographic and Reproductive Factors for 2,055 HPV Positive and 6,657 HPV 
Negative Women in the SPOCCS II Study, Stratified by Final Histology. 
 
Characteristic Normal 
HPV 
Negative 
N=6,657 
Normal 
HPV 
Positive 
N=1,405 
CIN I 
N=299 
CIN II 
N=167 
CIN III 
N=184 
Married (%) 99 98 97 96 99 
Median Age at First 
Intercourse (Range), years 20 (15-31) 20 (15-33) 
20  
(15-28) 
20  
(16-26) 
20  
(16-24) 
Intercourse within Four 
Months of Childbirth (%) 34 31 37 28 44 
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Median Number Lifetime 
Sexual Partners (range)    1 (1-27) 1 (1-10) 1 (1-8) 1 (1-10) 1 (1-12) 
Median Gravidity (range) 3 (0-13) 3 (0-9) 3 (0-8) 3 (0-10) 3 (0-8) 
Median Parity (range)   2 (0-8) 2 (0-7) 2 (0-5) 2 (0-5) 2 (0-5) 
Median Number of Abortions 
(range) 0 (0-9) 0 (0-9) 0 (0-4) 0 (0-4) 0 (0-4) 
 
 
2. Methods for the Study       
Statistical analysis for this study was two-fold. First, through risk-factor profiles we 
determined if CIN II should be grouped with CIN III as is current practice or if it is more similar 
to CIN I (see specific aim 1). Second, we attempted to answer the question of why some women 
in the SPOSSC II trial had cervical disease of a higher grade than others, with a focus on common 
reproductive risk factors (see specific aim 2).  
Data from the SPOCCS II trial was analyzed generating odds ratios for the association 
between multiple covariates including number of pregnancies, number of live births, age, and 
HPV infection/cervical intraepithelial neoplasia CIN I, CIN II and CIN III.  
a. Classification of the Exposure  
Exposure to oncogenic HPV infection was gathered by both self-collected cervical vaginal 
specimens and physician-collected samples from the cervix. These samples were evaluated for 
thirteen high-risk oncogenic HPV deoxyribonucleic acid (DNA) types (HPV 
16,18,31,33,35,39,45,51,52,56,58,59, and 68) using the Digene second-generation hybrid-capture 
assay [65]. Per manufacturers’ instructions, a value of ≥1.0 pg/ml HPV DNA was used as the cut-
off for positivity.  
A standardized questionnaire was administered in a confidential setting by trained health 
workers to elicit information on risk factors potentially associated with cervical cancer and its 
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precursors, including sexual, diet, and reproductive history (please see the appendix for a copy of 
the questionnaire).  
b. Classification of the Outcome 
Outcome data in this study was based on cervical biopsy specimens from SPOCCS II. The 
biopsy protocol is as follows: Women with abnormal cytology results and/or HPV positive test 
results were examined by a colposcope and biopsies were collected with a two-mm bronchoscopy 
biopsy instrument.  The cervix was examined by quadrant and all colposcopically detected 
cervical abnormalities were biopsied. In quadrants that appeared normal, biopsies were still 
obtained at the squamo-columnar junction at 2, 4, 8, and 10 o’clock depending on the quadrant. 
Endocervical curettage (ECC) was also performed. Therefore all participants colposcoped had a 
minimum of five biopsies including the ECC.  
c. Comparison Group Selection 
In general the comparison group should be selected from the population that also gave rise to 
the cases. For cervical cancer cases this population is women who are infected with HPV. 
It has been noted that a comparison group defined this way likely attenuates the risks 
associated with cofactors (i.e. parity) that are associated with the acquisition and potential 
persistence of HPV infection, so it avoids potential residual confounding by HPV [40, 66]. 
Munoz and colleagues suggest that studies including HPV negative women among the controls in 
case-control studies might have underestimated the influence of parity [5]. Researchers have 
highlighted the fact that while this many not be the best comparison group it is the achievable 
one. The most accurate comparison group would be one containing women who were infected 
with HPV at the same age as the cases but who did not go on to develop cervical cancer [40, 66].  
Women without HPV infection were included in identical analyses to estimate the change in odds 
ratio associated with their inclusion.  
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3. Data Management 
A strict system of data management was utilized in the SPOCCS II trial. At the first visit, all 
women were assigned a confidential code. All identifiers were removed from the data and kept in 
a locked separate file. For the purpose of this research women are identified by their code only.  
All data forms in SPOCCS II were collected and transported to the Cancer Institute Hospital, 
Academy of Medical Sciences (CICAMS) in Beijing where the data was entered, managed and 
cleaned. The “cleaning” procedures for the SPOCCS II data included quality control procedures 
employing range checks and assessment of completeness and consistency across variables.  
Further data management was performed at the National Cancer Institute (NCI) when the data 
was being prepared for additional analyses. To ensure uniformity across epidemiologic analyses 
performed using the SPOCCS II data, the dataset from the NCI was utilized for these analyses.   
4. Data Analysis 
a. Specific Aim 1  
Estimates of median values and proportions of women with suspected risk factors for CIN 
were calculated, stratified by histological status. Prevalence odds ratios and corresponding 95% 
confidence intervals for grades of CIN were calculated by unconditional multiple logistic 
regression, adjusted for age (in 3 groups: 35-39, 40-44, 45-50 years). Models were restricted to 
HPV positive women to reduce residual confounding by HPV infection [66]. 
Modeling strategies have been tested to ensure the correct adjustment for HPV is made. 
Using the IARC series of case-control studies, Castellsague and colleagues estimated the impact 
of different HPV adjustment strategies on the association of environmental cofactors and invasive 
cervical cancer risk. Three models were fitted for each cofactor. Of the three strategies tested, 
models that were restricted to HPV positive subjects yielded higher associations (1.1- 2.0 fold 
higher) than those derived from HPV adjusted models [3]. If HPV restriction is seen as the 
strictest approach to HPV adjustment, models that adjust for HPV rather than restrict the analysis 
could be underestimating the magnitude of the association. The same study concluded that 
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regardless of the strategy that they used the same conclusions were reached regarding the 
direction and statistical significance of the association between the cofactor and invasive cervical 
cancer [3]. In the present analyses, HPV-restricted models were utilized to analyze the potential 
associations between the cofactors and invasive cervical cancer.  
Parity was defined as a woman’s number of live births and gravidity as the number of 
pregnancies. As few women reported having never been pregnant (72 women, 0.8%) and few 
were nulliparous (i.e. no previous live births, 1.2%), the parity variable was collapsed into a 
binary variable (0-2 and ≥ 3). 
Models were reduced using backward elimination [67, 68] until only those variables 
producing a change ≥10% remained. Pregnancy and live births were highly correlated and thus 
not included in the same model. The final multivariate model included terms for age, number of 
pregnancies, intercourse within four months of childbirth, and number of induced abortions. 
Results of models restricted to HPV positive women and to those that adjusted for HPV status 
were completed. All analyses were performed using Stata 8.0 and Stata 9.0 analytic software 
(Stata Corp. LP, College Station, Texas). 
b. Specific Aim 2 
Two sets of cross-sectional analyses were designed.  The first was restricted to only HPV 
positive women [66]. A strict assessment of cofactors requires a study group that is known to be 
exposed to HPV. Based on results from the analyses performed for specific aim 1 we altered the 
stratification of the outcome in these analyses. Odds ratios and 95% confidence intervals are 
presented for each cofactor tested for comparisons of CIN III vs. ≤ CIN II and for CIN I and/or 
HPV positive women vs. HPV negative women.  
Variable categories were examined and recoded if necessary. Univariate distributions of the 
variables of interest were then examined. Please see the appendix for a list of the variables of 
interest. These variables (i.e. number of pregnancies, number of live births, smoking history, self-
report of sexually transmitted disease [STD] history) are important since there are hypotheses 
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stating that cervical trauma, smoking status, co-infection with other STDs are important cofactors 
for the progression of HPV infection to invasive cervical cancer [48, 69-72].    
A second analysis was completed where HPV was adjusted for in the model. Women 
negative for HPV infection were included in the analyses as there may be cofactors that act to 
make women more susceptible to HPV infection. In these models other potential confounders of 
the HPV and CIN relationship were evaluated by using the same backward elimination method 
[67, 68]. First, all potential confounders were included in the full model. Second, using the 
epiconf procedure in STATA the difference in the crude and adjusted estimates when the 
potential confounder was removed from the model was calculated. Confounders were eliminated 
until only those variables producing a change ≥10% in the point estimate for the main exposure 
remained in the model. Those remaining variables were considered confounders of the 
relationship between HPV and CIN.  
c. Power Calculation  
 
The crude odds ratio of the association between number of pregnancies and CIN III vs. ≤ CIN 
II is 1.6 [95% CI (1.1, 2.2)]. Table 4 shows the levels of power to detect odds ratios from 1.3 to ≥ 
4 for the analyses. Power calculations were completed using Episheet [73, 74]. 
 
 
Table 4. Power to detect associations between number of pregnancies and CIN III vs. ≤ CIN II 
with 184 cases of cervical cancer. 
 
Odds Ratio Power for HPV+ control 
group (n=1,871) 
Power for HPV+ and HPV- 
controls (n=8,580) 
1.3 35% 37% 
1.5 68% 71% 
2.0 98% 98% 
3.0 99% 99% 
 1919 
4.0 or greater 100% 100% 
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IV. METHODS 
 
 
CHAPTER IV 
 
RESULTS 
 
A. Manuscript 1. Risk factors for cervical intra-epithelial neoplasia II seem more similar to 
grade I than grade III  
 
1. Introduction 
Infection of the cervix with Human Papillomavirus (HPV) does not uniformly lead to 
histologic changes. Viral replication within cells and integration into the DNA of the cervical 
cells causes the range of cellular changes seen microscopically in biopsy specimens. Dysplastic 
changes, termed cervical intraepithelial neoplasia (CIN), are classified in three grades based on 
increasing degrees of cellular change and disorganization. Although CIN was initially described 
as a continuum of histological changes (all of which were considered true precursors of invasive 
disease if untreated) [27], our understanding of the natural history of cervical neoplasia has since 
been revised [27, 30] to acknowledge that CIN does not inevitably progress through each higher 
grade of CIN to cancer. When dysplasia progresses, it is thought to be orderly, i.e. not “skipping” 
from lower grades to cancer. However, progression between some levels, for instance CIN I to 
CIN II, is the exception rather than the rule. Consequently, the classification of cervical cancer 
precursors by histology may need revision to more accurately reflect natural history of disease 
progression and to better inform clinical decision making [27]. Currently, a two-tiered 
histological grouping has been adopted [1] (CIN I, CIN II/III) to reflect putative differences in the 
natural history between CIN I (lower probability of progressing) and CIN II/III (a dysplastic 
process with a greater likelihood of progression to cancer) [1]. 
Recent research suggests CIN II may not be a discrete histological grade that can be reliably 
classified, but instead an overlap between CIN I (a non-neoplastic HPV infection) and CIN III ( a 
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neoplastic cervical cancer precursor) [2, 31]. It has been hypothesized that a proportion of CIN II 
lesions are biologically similar to CIN I and have greater probability of regressing over time, 
while other CIN II lesions are more characteristic of CIN III lesions [2]. If the current construct of 
CIN II is confirmed to behave more like CIN I or CIN III lesions, future clinical treatment 
guidelines for women, especially young women with CIN II diagnoses, may need to be 
reevaluated. Under consideration would be differential re-screening and treatment options, as 
well as incorporation of more sophisticated markers of risk of progression.  
In order to describe whether CIN II lesions are epidemiologically more like CIN I or CIN III 
lesions in terms of the risk predictors among women with these diagnoses, we used data from a 
cross-sectional study in China: the Shanxi Province Cervical Cancer Screening Study II 
(SPOCCS II) [14]. In this population-based study, women were screened for cervical cancer. 
Women with cytological abnormalities and/or those who tested positive for cervical HPV DNA 
were triaged to colposcopy for universal histological confirmation of cervical disease status. Our 
primary aim was to determine if histologically confirmed CIN II lesions had risk factor profiles 
that more closely resembled CIN I or CIN III cases. We present results examining differences in 
the risk factor profiles among HPV DNA positive women with histological diagnoses of CIN I, 
CIN II and CIN III.  
 
2. Materials and Methods 
Subject recruitment, study design. Between May 2001 and June 2002, the SPOCCS II 
cervical cancer screening study was conducted in Yangcheng and Xiangyuan counties, Central 
China, as previously described [14]. In brief, women aged 35 to 50 years were invited to 
participate in a cross-sectional, cervical cancer collaborative project between the Cancer Institute 
of the Chinese Academy of Medical Sciences in Beijing, China and the Cleveland Clinic 
Foundation in Cleveland, Ohio. A cluster-sampling frame was used, where communes within 
each county were the unit for the cluster. Eligibility criteria included being a resident of one of 15 
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county communes, non-pregnant, having an intact uterus, no history of pelvic irradiation or 
cervical cancer, and no screening within the last five years. Of a total of 9,034 women attending 
the Xiangyuan Women’s and Children’s Clinic and the Yangcheng Cancer Hospital, 8,798 
women (97%) met study eligibility criteria.  
A standardized questionnaire was administered in a confidential setting by trained health 
workers to elicit information on risk factors potentially associated with cervical cancer and its 
precursors, including sexual, diet, and reproductive history. All participating women performed a 
self-collected HPV test. Approximately 10 months later (range 3-16 months), women underwent 
a pelvic examination by a study staff physician to collect cervical cell samples for cytology and 
HPV testing. For women with abnormal cytology results and/or HPV positive test results, they 
were examined by a colposcope and biopsies collected with a two-mm bronchoscopy biopsy 
instrument.  The cervix was examined by quadrant and all colposcopically detected cervical 
abnormalities were biopsied. In quadrants that appeared normal, biopsies were still obtained at 
the squamo-columnar junction at 2, 4, 8, and 10 o’clock depending on the quadrant. Endocervical 
curettage (ECC) was also performed. Therefore all participants colposcoped had a minimum of 
five biopsies including the ECC.  
Study protocol and questionnaires were approved by human subjects review boards of the 
Cancer Institute/Hospital of the Chinese Academy of Medical Sciences, and the Cleveland Clinic 
Foundation.  
HPV DNA Detection. Both self-collected cervical vaginal specimens and physician collected 
samples from the cervix were evaluated for thirteen high-risk oncogenic HPV DNA types (HPV 
16,18,31,33,35,39,45,51,52,56,58,59, and 68) using the Digene second-generation hybrid-capture 
assay [65]. Per manufacturers’ instructions, a value of ≥1.0 pg/ml HPV DNA was used as the cut-
off for positivity. In this paper oncogenic HPV DNA will be referred to as HPV. 
Statistical Analyses. Estimates of median values and proportions of women with suspected 
risk factors for CIN were calculated, stratified by histological status. Prevalence odds ratios 
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(ORs) and corresponding 95% confidence intervals (CIs) for grades of CIN were calculated by 
unconditional multiple logistic regression, adjusted for age (in 3 groups: 35-39, 40-44, 45-50 
years). Models were restricted to HPV positive women to reduce residual confounding by HPV 
infection [66]. Models were reduced using backward elimination [67, 68] until only those 
variables producing a change ≥10% remained. Pregnancy and live births were highly correlated 
and thus not included in the same model. The final multivariate model included terms for age, 
number of pregnancies, intercourse within four months of childbirth, and number of induced 
abortions. 
Parity was defined as a woman’s number of live births and gravidity as the number of 
pregnancies. As few women reported having never been pregnant (72 women, 0.8%) and few 
were nulliparous (i.e. no previous live births, 1.2%), the parity variable was collapsed into a 
binary variable (0-2 and ≥ 3).  
An analysis was conducted to compare results of models restricted to HPV positive women 
to those that adjusted for HPV status. Analyses were performed using Stata 8.0 and Stata 9.0 
analytic software (Stata Corp. LP, College Station, TX). 
 
3. Results 
Overall, a total of 8,798 women participated, of whom 4% had histologically-confirmed CIN 
I, 2% had CIN II and 2.1% had CIN III. Prevalence of HPV increased from 85.2% among women 
with CIN-1 to 97.4% for CIN-3. Of the 8,062 women with normal histology, 1,405 (17.4%) were 
HPV positive. Infection with HPV was associated with an increased risk for CIN II versus CIN I 
[OR= 5.0 (2.1, 11.9)], however, no difference in HPV prevalence was found when comparing 
CIN III versus CIN II cases: [OR =1.3 (0.39, 4.4)]. 
Among 2,055 women who tested positive for HPV, the prevalence of histologically 
confirmed CIN was as follows: 14.4% had CIN I, 8.0%  had CIN II, and 8.9% had CIN III (Table 
1). The majority with HPV infection (67.7%) were histologically normal (negative for CIN). 
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Participants’ median age ranged from 40 years for women who were HPV positive and less than 
or equal to CIN I, to 43 years for HPV positive and CIN III.  
More than 96% of women were married; most reported having one lifetime sexual partner. 
Independent of the grade of cervical disease, women had a median number of two live births and 
three pregnancies, with a median age at first intercourse of 20 years. Most women use female 
sterilization as their contraceptive method and this also did not vary by grade of CIN. The 
proportion of women reporting intercourse within four months of childbirth differed by 
histological grade, and  ranged from 28 to 44%.  
Age-adjusted and multivariate models for CIN II versus CIN III and CIN I. Age did not 
appear to be associated with risk of higher histological grade of cervical neoplasia (Table 2). An 
increased risk of CIN III versus CIN II was seen for higher gravidity (≥ 3 pregnancies) [OR=1.6 
(1.0, 2.6)] and sexual intercourse within four months of childbirth [OR=2.0 (1.3, 3.2)]. Risks 
associated with reproductive factors appeared comparable for CIN II and CIN I, except an inverse 
association was observed for sexual intercourse within four months of childbirth for CIN II versus 
CIN I [OR= 0.64 (0.42, 0.97)]. All observed associations were of the same magnitude in the 
multivariate models (Figure 1). For comparisons of CIN II separately to CIN III and to CIN I, no 
associations were found for educational attainment, history of vaginal discharge, numbers of 
home deliveries, number of live births, number of induced abortions or current method of 
contraception. Results from HPV restricted models and HPV adjusted models for CIN II versus 
CIN III and CIN I were nearly identical (data not shown).  
Multivariate models for CIN III versus ≤ CIN II and CIN II/III  versus ≤ CIN I. Women over 
age 45 years showed an increased risk of having a diagnosis of CIN III versus ≤ CIN II [OR=1.9 
(1.3, 2.8) versus women 35-40 years] (Table 3). Higher number of births (≥ 3 live births) was 
associated with a 70% greater risk of CIN III (versus ≤ CIN II) compared to women with fewer 
than three births. Intercourse within four months of childbirth was also associated with CIN III 
(versus ≤ CIN II) [OR = 1.8 (1.3, 2.5)].  No associations for CIN III (versus ≤ CIN II) were found 
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for lifetime number of sexual partners, number of live births, or number of abortions. When 
multivariate models were re-run for CIN II/III (versus ≤ CIN I), no associations remained 
statistically significant, with the exception of age over 45 years [OR=1.8 (1.3, 2.4 versus women 
35-40 years)].  
 
4. Discussion 
This study of 2,055 HPV positive women, all with a minimum of five biopsies, in Shanxi 
Province, China, provides evidence that risk factors for histologically-confirmed CIN II are more 
similar to those for CIN I than for CIN III.  Information on risk factors was obtained through 
private interviews, conducted in the local dialect by trained interviewers, using a previously 
piloted questionnaire. When comparing CIN risk-factor profiles, they diverged for CIN II 
compared to CIN III, but were broadly similar for CIN II compared to CIN I. If CIN III and CIN 
II are biologically similar, we would expect the risk factor profiles to be more similar for CIN III 
and CIN II. Instead, risk factor profiles between CIN II and CIN I cases were more similar. Based 
on these results, CIN II is more similar to CIN I and may represent non-neoplastic HPV 
infections rather than a direct cervical cancer precursor such as CIN III. Multivariate models 
comparing CIN III versus ≤ CIN II were similar to CIN III versus CIN II comparisons.  In 
contrast, no risk factors, other than age, were identified as meaningfully different in comparisons 
of the combined category CIN II/III to ≤ CIN I, reinforcing our assumption that CIN II and CIN I 
are more similar that CIN II and CIN III. 
Our study is one of the few of sufficient size and uniform use of histology that is able to 
directly compare CIN III to CIN II. It builds on previous findings that CIN II lesions may not be 
more biologically similar to CIN III, at least as reflected in risk factor profiles [31, 75, 76]. For 
example, among 2,366 women with oncogenic HPV enrolled in the U.S. ALTS trial, smoking 
was strongly associated with a diagnosis of ≥ CIN III, but was not associated with a diagnosis of 
CIN II, except among women with HPV-16 [31]. No significant differences in reproductive 
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factors were found between women diagnosed with CIN II or CIN III, when compared to ≤CIN I 
in ALTS [77] (as found in our Chinese study), although the number of ALTS participants 
reporting three or more pregnancies or live births was limited. Too few women in our study from 
China smoked in order to examine this risk factor with sufficient power. Further evidence that the 
characteristics and behaviors of CIN II may be distinct from CIN III includes data from a large 
population-based prospective study among women with HPV infection that found that time from 
last normal cytological smear was a risk factor for prevalent CIN III, but not for ≤CIN II [76].   
Although population-based, our findings from two rural counties in Shanxi province cannot 
be considered representative of the entire Chinese population. Reliance on self-reported data may 
have led to under or over reporting of reproductive variables. Self-reported data are always 
difficult to verify, but due to the one child policy in China there has been strong incentive to have 
reliable reproductive information and to report pregnancies, abortions, live and still births to the 
government [78]. Although there was a large range in the numbers of pregnancies (0-10) and live 
births (0-10), these numbers were compared to means for the province (typical for a rural 
environment) and they fell within normal limits.  
We realize there may be concern with our histological diagnoses due to inherent difficulties 
in obtaining standardized pathological diagnoses. Many studies report on the poor reproducibility 
of CIN II versus CIN III, and CIN I versus HPV changes. Interobserver variation for diagnosing 
CIN II is greater than for CIN III [75].  A potentially large proportion of CIN II cases could be 
misclassified and actually be true CIN I cases. In order to describe potential changes in estimates 
related to misclassification, estimates were recalculated using data from a review of study 
biopsies. Biopsies from SPOCCS I (a SPOCCS II precursor) were recently reviewed for 
agreement and the proportion of biopsies said to be misclassified were applied to the results from 
this study: on review, 92% remained CIN 2, 2.4% CIN 1, 4.8% normal histology and 1.2% CIN 
3). Odds ratios and 95% CI, from the present study, were recalculated for higher gravidity (≥ 3 
pregnancies), where no change in the magnitude of the effect was observed. Given the result of 
 27 
the quality control study including double-reading of pathology slides, the change in the 
magnitude of the effect was small, suggesting that misclassification of CIN was negligible in this 
study. The fact that 92% of CIN II remained classified as CIN II would suggest it can in fact be 
sorted into a histological classification distinguishable from CIN I and CIN III. Epidemiologic 
data from this study would suggest that CIN II has biologic characteristics more similar to CIN I 
rather than the conventional grouping with CIN III. It further suggests that studies who choose to 
group CIN II with CIN III are differentially misclassifying CIN II and diluting the effect of 
covariates as they relate to CIN III.  Data from prospective studies is needed that follows women 
with untreated CIN II to document the natural history see if it behaves more like CIN III or CIN I. 
These preliminary data would lead us to hypothesize the latter.     
Our study results are consistent with others that suggest that CIN II may represent a more 
heterogeneous group of lesions than originally believed. If confirmed to be true by future 
prospective studies, different treatment options may need to be considered for a proportion of 
women with CIN II diagnoses in order to avoid potential over-treatment. Current 
recommendations are to treat women with histologically confirmed CIN II or CIN III with either 
ablative (e.g. cryotherapy) or excisional treatment (e.g. loop electrocautery excision procedure, 
conization) [79]. While clinical trials have generally failed to show differences in treatment 
modalities [80-82], excisional treatment allows for pathologic diagnosis of the excised tissue. 
Excision is often the treatment of choice and is always recommended for women with 
unsatisfactory colposcopy, or recurrent disease [79]. Treatment of CIN is not without 
complications, especially for women who are still in their childbearing years [83]. While 
uncommon, significant pregnancy complications have been associated with larger loop 
electrosurgical excision procedure [84-86]. Treatment of CIN II may require review; more 
research is needed to see if our findings are confirmed in other studies.  
In conclusion, our data add to the accumulating evidence that a substantial proportion of CIN 
II may be biologically different from CIN III, sharing more similarities to CIN I. We encourage 
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those with prospective data to perform case-case analyses to identify risk factor differences 
among the histologic cervical grades.  
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Table 5. Selected Characteristics of Study Participants among 2,055 HPV DNA Positive Women in the SPOCCS II Study,  
Stratified by Histology. 
 
Characteristic HPV Positive 
Normal Cytology 
N=1,405 
CIN I 
N=299 
CIN II 
N=167 
CIN III 
N=184 
Proportion of all HPV Detected Lesions (%) 67.7 14.4 8.0 8.9 
Median Age (range), years     40 (35-50) 40 (35-50) 41 (35-50) 42 (35-50) 
Percent Married (%) 98 97 96 99 
Median Age at First Intercourse (range), years 20 (15-33) 20 (15-28) 20 (16-26) 20 (16-24) 
Percent Having Intercourse Within Four Months of  
Childbirth (%) 
31 37 28 44 
Median Number of Lifetime Sexual Partners (range) 1 (1-10) 1 (1-8) 1 (1-10) 1 (1-12) 
Median Number of Pregnancies (range) 3(0-9) 3 (0-8) 3 (0-10) 3 (0-8) 
Median Number of Live Births (range) 2 (0-7) 2 (0-5) 2 (0-5) 2 (0-5) 
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Table 6. Age-adjusted1 Odds Ratios for Selected Characteristics among HPV DNA positive Women in the SPOCCS II Study,  
Comparisons by Histology  
 
 
Characteristic 
 
CIN III vs. CIN II 
 
Cases/Controls          OR (95%CI) 
 
CIN II vs. CIN I 
 
   Cases/Controls         OR (95%CI) 
Age (years) 
   35-39 
   40-44 
   45-50 
 
62/62 
52/55 
70/50 
 
1.0 
0.95 (0.56, 1.6) 
1.4 (0.84, 2.3) 
 
62/142 
55/81 
50/76 
 
1.0 
1.6 (0.99, 2.5) 
1.5 (0.95, 2.4) 
Educational Attainment 
    None  
    Primary  
    Middle 
    Over Senior high 
 
12/12 
62/49 
89/75 
21/31 
 
1.0 
1.2 (0.51, 3.0) 
1.2 (0.52, 3.0) 
0.73 (0.27, 2.0) 
 
12/16 
49/90 
75/140 
31/53 
 
1.0 
0.74(0.32, 1.7) 
0.79 (0.35, 1.8) 
0.89 (0.37, 2.2) 
Age at First Intercourse (years) 
    ≥ 21 
   19-20    
   
 
67/71 
41/31 
 
 
1.0 
1.2 (0.76, 2.0) 
 
 
71/114 
31/64 
 
 
1.0 
0.86 (0.56, 1.3) 
 
 31 
31 
   12-18 76/65 1.3 (0.70, 2.3) 31/64 0.71 (0.41, 1.2) 
Lifetime Sexual Partners 
    1 
    2 
    ≥ 3 
 
122/107 
26/37 
36/23 
 
1.0 
0.63 (0.36, 1.1) 
1.4 (0.75, 2.5) 
 
107/174 
37/74 
23/51 
 
1.0 
0.82 (0.51, 1.3) 
0.75 (0.43, 1.3) 
Reported # Pregnancies 
    0-2 
    ≥ 3 
 
50/64 
134/103 
 
1.0 
1.6 (1.0, 2.6) 
 
64/104 
103/195 
 
1.0 
0.84 (0.56, 1.3) 
Reported # Live Births 
    0-2 
    ≥ 3 
 
126/108 
57/58 
 
1.0 
0.78 (0.49, 1.2) 
 
108/202 
58/96 
 
1.0 
1.1 (0.71, 1.6) 
Intercourse Within Four Months of 
Childbirth         
    No 
    Yes 
 
103/120 
80/46 
 
1.0 
2.0 (1.3,  3.2) 
 
120/187 
46/111 
 
1.0 
0.64 (0.42, 0.97) 
Reported # Abortions  
    None 
   
 
113/111 
 
 
1.0 
 
 
111/199 
 
 
1.0 
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  1  
  ≥ 2 
41/37 
29/18 
1.1 (.66, 1.9) 
1.7 (.89, 3.3) 
37/57 
18/42 
1.1 (.71, 1.8) 
0.79 (.43, 1.5) 
Current Contraception Use  
    Female Sterilization 
    Intrauterine Device 
    Oral Contraceptives 
    Condoms 
    None 
 
158/132 
15/19 
2/4 
0/1 
9/11 
 
1.0 
0.72 (.35, 1.5) 
0.45 (.08, 2.5) 
- 
0.71 (.28, 1.8) 
 
132/237 
19/44 
4/3 
1/1 
11/14 
 
1.0 
0.80 (.45, 1.4) 
2.8 (.60, 12.7) 
2.4 (.14, 38.4) 
1.5 (.64, 3.3) 
1Age adjustment was by categorical years as follows; 35-39, 40-44, 45-50. 
 
Note: Numbers rounded to 1.
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Table 7. Odds Ratios for Selected Characteristics Among all Women in the SPOCCS II Study, Comparisons by Histology 
 
 
Characteristic 
 
CIN III vs. ≤ CINII 
 
Cases/Controls                 ORs (95%CI)1 
 
CIN II/III vs. ≤ CIN I 
 
   Cases/Controls                  ORs  (95%CI)1 
Age (years) 
   35-39 
   40-44 
   45-50 
 
62/824 
52/598 
70/449 
 
1.0 
1.1 (0.78, 1.7) 
1.9 (1.3, 2.8) 
 
124/762 
107/543 
120/399 
 
1.0 
1.2 (0.90, 1.6) 
1.8 (1.3, 2.4) 
Reported # of Pregnancies 
    0-2 
    ≥3 
 
50/688 
134/1183 
 
1.0 
1.7 (1.1, 2.5) 
 
114/624 
237/1080 
 
1.0 
1.2 (0.92, 1.6) 
Intercourse Within Four Months of 
Childbirth 
    No 
    Yes 
 
 
103/1274 
80/584 
 
 
1.0 
1.8 (1.3, 2.5) 
 
 
223/1154 
126/538 
 
 
1.0 
1.2 (0.96, 1.6) 
Reported # of Abortions 
     None 
     1  
 
113/1177 
41/452 
 
1.0 
0.76 (0.50, 1.1) 
 
224/1066 
78/415 
 
1.0 
0.83 (0.61, 1.1) 
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   ≥ 2 
 
29/229 
 
1.0 (0.62, 1.6) 
 
47/211 
 
0.99(0.67, 1.5) 
1Models adjusted for all variables in the table. 
 
Note: Age adjustment was by categorical years as follows; 35-39, 40-44, 45-50.  
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Figure 2. Multivariate Odds Ratios and 95% Confidence Intervals for Selected Factors for CIN    
III  vs. CIN II among Women in the SPOCCS II Trial. 
 
 
 
1 Variable in the model was pregnancies 0-2 vs. 3+  
 
2 Variable in the model was intercourse within four months of childbirth (yes/no).
 
 
Age 40-44 vs. 35-39 
Age 45-50 vs. 35-39 
Pregnancies1
Intercourse2 
Abortion 1 vs. 0 
Abortion 2+ vs. 0
Variable 
0.97 (0.58, 1.62)
1.30 (0.76, 2.22)
1.90 (1.12, 3.24)
2.10 (1.30, 3.39)
0.80 (0.45, 1.41)
1.10 (0.53, 2.27)
OR (95% CI)
 
 
 
 
 
 
 
   1.25 .5 2 4 8
Odds ratio (log scale)
CIN III vs. CIN II 
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Figure 3. Multivariate Odds Ratios and 95% Confidence Intervals for Selected Factors for CIN II 
vs. CIN I Among Women in the SPOCCS II Trial. 
 
 
1 Variable in the model was pregnancies 0-2 vs. 3+  
 
2 Variable in the model was intercourse within 4 months of childbirth yes/ no 
 
 
Age 40-44 vs. 35-39 
Age 45-50 vs. 35-39 
Pregnancies1 
Intercourse2 
Abortion 1 vs. 0 
Abortion 0 vs. 2+ 
Variable 
1.50 (0.96, 2.34) 
1.50 (0.94, 2.41) 
0.74 (0.46, 1.18) 
0.63 (0.42, 0.95) 
1.30 (0.76, 2.23) 
0.97 (0.50, 1.89) 
OR (95% CI)
 
 
 
 
 
 
 
  1.25 .5  2 4 8
Odds ratio (log scale)
 
CIN II vs. CIN I 
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B. Manuscript 2. Reproductive risk factors for Human Papillomavirus infection and 
cervical intraepithelial neoplasia III in the Chinese SPOCCS II study.  
 
1. Introduction 
Worldwide, invasive cervical cancer (ICC) is the second most common cancer in women 
with approximately 470,000 new cases [11].  Oncogenic types of Human Papillomavirus (HPV) 
infection have clearly been established as a necessary cause of cervical cancer. The contrast 
between the high lifetime cumulative incidence of cervical HPV infection and the relatively low 
lifetime risk of cervical cancer suggests the influence of other etiologic cofactors that act in 
conjunction with HPV to increase a woman’s risk of cervical carcinogenesis. Thus, further 
understanding of HPV co-factors that increase a woman’s risk of progression from cervical HPV 
infection to ICC is warranted. Candidate cofactors may be split into three groups [3]: 1) 
environmental cofactors, such as use of oral contraceptives, smoking, diet, and cervical trauma; 
2) viral cofactors, such as infection with multiple HPV types or infection with specific oncogenic 
types; and 3) host factors, such as factors related to the host’s immune response and endogenous 
hormones. 
Factors related to reproduction have been associated with both the risk of HPV infection (e.g. 
early onset intercourse, multiple partners) [26] and the risk of developing cervical cancer among 
HPV DNA positive women (e.g. parity) [5, 10]. Specific reproductive factors could act as HPV 
cofactors within any of the three aforementioned categories: 1) Environment: cervical trauma, 
temporary exogenous hormonal exposure [3]; 2) Viral type: HPV viral types acquired and timing 
of acquisition during pregnancy or postpartum [3] ; 3) Host: modification of immune responses 
during pregnancy or change of estrogenization of tissues during lactation [3].  It is not clear 
however in which part of the carcinogenic process reproductive factors may play a role [87]. 
Some may increase a woman’s susceptibility to HPV infection while others affect the probability 
of an infection becoming persistent, while still others may affect progression from one 
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histological state to another more serious grade of cervical disease [87]. Figure 4 is a proposed 
causal diagram for the relationship between oncogenic HPV infection, reproductive risk factors 
and CIN III. Further, little is known concerning whether host factors related to the successful 
progression of a pregnancy to a live birth might also be related to the risk of progression of HPV 
infection to CIN III.  
In a previous publication, we determined that risk factors for CIN II are more similar to CIN I 
than CIN III. In order to investigate reproductive risk factors, we have utilized this information 
and present here reproductive risk factors for CIN III versus ≤ CIN II from a large cross-sectional 
study in rural China. Differences in risk factor profiles are also presented by comparing women 
with either CIN I or HPV DNA, to HPV-negative women with normal cytology from a study of 
population-based samples of women screened for cervical cancer. All women with cytological 
abnormalities and/or HPV DNA positive results were referred to colposcopy for histological 
confirmation of cervical disease status. Our aim was to determine whether reproductive risk 
factors may increase a woman’s likelihood of current HPV infection (association with CIN 
I/HPV) or the likelihood that an HPV infection will progress to high-grade dysplasia (association 
with CIN III). 
 
2. Materials and Methods 
Subject recruitment, study design. Between May 2001 and June 2002, the SPOCCS-II 
cervical cancer screening study was conducted in Yangcheng and Xiangyuan counties, Central 
China, as previously described [14]. In brief, women aged 35 to 50 years were invited to 
participate in a cross-sectional, collaborative cervical cancer project between the Cancer Institute 
of the Chinese Academy of Medical Sciences in Beijing, China and the Cleveland Clinic 
Foundation in Cleveland, Ohio. A cluster-sampling frame was used, where communes within 
each county were the units for the clusters. Eligibility criteria included being a resident of one of 
15 county communes, non-pregnant, having an intact uterus, no history of pelvic irradiation or 
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cervical cancer, and no screening within the last five years. Of a total of 9,034 women attending 
the Xiangyuan Women’s and Children’s Clinic, 8,798 women (97%) met study eligibility criteria.  
A standardized questionnaire was administered in a confidential setting by trained health 
workers to elicit information on risk factors potentially associated with cervical cancer and its 
precursors, including sexual, diet, and reproductive history. All participating women performed a 
self-collected HPV test [14, 88]. After approximately 10 months (range 3-16), women underwent 
a pelvic examination by a study staff physician to collect cervical cell samples for cytology and 
HPV DNA testing. All women with abnormal cytology results and/or HPV-positive test results 
on either sample, were examined with a colposcope and biopsies were collected with a 2-mm 
bronchoscopy biopsy instrument. The cervix was examined by quadrant and all colposcopically 
detected cervical abnormalities were biopsied. In quadrants that appeared normal, biopsies were 
still obtained at the squamo-columnar junction at 2, 4, 8, and 10 o’clock depending on quadrant. 
Endocervical curettage (ECC) was also performed. Therefore all participants had a minimum of 
five biopsies including the ECC. 
Study protocol and questionnaires were approved by human subjects review boards of the 
Cancer Institute/Hospital of the Chinese Academy of Medical Sciences, and the Cleveland Clinic 
Foundation.  
HPV DNA Detection. Both self-collected cervico-vaginal specimens and physician collected-
samples were evaluated for thirteen high-risk oncogenic HPV types (HPV 
16,18,31,33,35,39,45,51,52,56,58,59, and 68) using the Digene second generation hybrid capture 
assay (HC II) [65]. Per manufacturers’ instructions, a value of ≥1.0 pg/ml HPV DNA was used as 
the cut-off for positivity. HPV DNA testing was performed blinded to other test results.  HPV 
DNA will be hence referred to as HPV.   
Statistical Analyses. Estimates of medians and proportions of suspected risk factors for CIN 
were calculated, stratified by histological status. Prevalence odds ratios (ORs) and corresponding 
95% confidence intervals (CIs) for grades of CIN were calculated by unconditional multiple 
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logistic regression, adjusted for age (categorized into 3 groups: 35-39, 40-44, 45-50 years). 
Models were restricted to HPV-positive women to reduce residual confounding by HPV infection 
[66], with the exception of the model comparing women with either CIN I or HPV DNA (CIN 
I/HPV positive cytology normals) versus HPV-negative women with normal cytology. Potential 
confounders examined included age, educational attainment, age at first intercourse, number of 
sexual partners, current contraceptive use, intercourse within four months of childbirth, and 
number of previous pregnancies, live births, or induced abortions. Model variables were 
eliminated using backward elimination [67, 68] until only those variables producing a change of 
≥10% remained. Pregnancy and live births were highly correlated and thus not included in the 
same model. Final multivariate models included terms for age, number of pregnancies, 
intercourse within four months of childbirth, number of induced abortions, number of sexual 
partners and the use of an intrauterine device for contraception.  
Parity was defined as woman’s number of live births and gravidity as the number of 
pregnancies. As few women reported having never been pregnant (72 women, 0.82%) or were 
nulliparous (i.e. no previous live births, 1.2%), the parity variable was collapsed into a binary 
variable (0-2 and ≥ 3).    
An analysis was conducted comparing results of models restricted to HPV positive women to 
those that adjusted for HPV status. Analyses were performed using Stata 8.0 and Stata 9.0 
analytic software (Stata Corp LP, College Station, TX). 
 
3. Results 
Among 8,798 women who participated in the SPOCC II study, 4% had histologically-
confirmed CIN I, 2% had CIN II and 2.1% CIN III (Table 1). HPV positivity was 85.2% among 
those with CIN I, 96.5% for CIN II, and 97.3% for CIN III. 17.4% of the 8,062 women with 
normal histology were HPV positive.  
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Of the 8,712 women for whom data was available on all variables, 76.4% were histological 
normal (CIN negative) without any detectable HPV DNA infection (n=1,405), 16.1% had HPV 
infection and normal histology (n=1,405), 3.4% had CIN I (n=299), 2% had CIN II (n=167), and 
2% had CIN III (n=184). Participants’ median age increased with higher histological grade, 
ranging from 40 years for women who were cytology-negative and HPV-positive to 43 years for 
HPV-positive CIN III.  
More than 96% of women were married; most reported having one lifetime sexual partner. 
Independent of the grade of cervical disease, women had a median number of two live births and 
three pregnancies, with a median age at first intercourse of 20 years. Most women use female 
sterilization as their contraceptive method and this also did not vary by grade of CIN. The 
proportion of women reporting intercourse within four months of childbirth differed by 
histological grade, and  ranged from 28 to 44%.  
The risk of CIN III versus ≤ CIN II was associated with older age: [OR= 2.1 (1.4, 3.0) for 45-
50 versus 35-44 years], higher gravidity (≥ 3 pregnancies) [OR=1.5 (1.0, 2.1) versus 0-2 
pregnancies] and sexual intercourse within four months of childbirth [OR=1.7 (1.2, 2.3)]. Women 
who reported using an intrauterine device (IUD) appeared to be at a lower risk of CIN III versus ≤ 
CIN II [OR= 0.52 (.30, .91) versus female sterilization]. No association was observed for a 
woman’s reported age at initiation of sexual intercourse [OR=1.3 (0.89, 1.8) 12-18 versus ≥ 21 
years], or reported number of sexual partners [OR=1.2 (.80, 1.8) ≥ 3 versus 1 partner] Results of 
the multivariate analyses (Figure 5) were similar to those in the age-adjusted analyses.  
When comparing women who had either CIN I or were HPV positive versus those that were 
dually negative for HPV and cytology, age was not associated with risk. Conversely, there 
appeared to be an increased risk for women who initiated sexual intercourse at ages 19-20  
[OR=1.3 (1.1, 1.5) versus ≥ 21 years)] and with a greater number of reported sexual partners (2 
versus 1) [OR=1.5 (1.3, 1.7)]. A nearly identical OR and CI was observed for women with ≥ 3 
sexual partners versus those reporting only one lifetime sexual partner. A woman’s number of 
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reported  pregnancies was not associated with CIN I/HPV DNA positivity. Results of multivariate 
analyses were generally the same, with the exception of age at first intercourse which after 
adjusting for number of sexual partners and number of abortions did not remain significant: [OR= 
1.10 (.93, 1.3) for 19-20 versus ≥ 21 years] and [OR=1.0 (.88, 1.14) for 12-18 versus ≥ 21 years] 
(Figure 6).   
No associations were seen for number of live births or any of the three constructed pregnancy 
success variables for both comparisons of cervical histological grades, in either the age- or 
multivariate-adjusted analyses. 
Risk factors for engaging in intercourse within four months of childbirth were examined 
among women with normal cytology, and included older age, fewer reported sexual partners and 
fewer reported pregnancies. Women who reported to have engaged in intercourse within four 
months of childbirth were also more likely to have ≤ 50% of pregnancies resulting in live birth. 
Women with normal cytology who used an IUD [OR=2.9 (2.5, 3.4)], oral contraceptives [OR=2.8 
(1.8, 4.3)], or no contraceptives [OR=1.3 (1.0, 1.7)] were also more likely to report having 
intercourse within four months of child birth versus those who were sterilized. Reported number 
of abortions and expected reproductive success were not associated with risk of CIN in any of the 
analyses. When abortions were excluded from the pregnancy success variable, the association 
increased rather than decreased risk [OR= 2.0 (1.2, 3.5).]  
 
4. Discussion 
This study of 8,712 women, all with a minimum of five biopsies, in Shanxi province, China 
provides evidence that selected reproductive risk factors, including having more than three 
pregnancies and a history of sexual intercourse within four months of childbirth may have a role 
in the progression to CIN III from lower grades of cervical disease. In contrast, susceptibility to 
CIN I/HPV infection did not appear to be clearly associated with the reproductive factors 
investigated in this survey, and was more clearly associated with a woman’s reported history of 
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lifetime sexual partners. Host factors related to the successful progression of pregnancy to live 
births were not shown to be related to either histological grade comparison. Information on risk 
factors was obtained through private interviews, conducted in the local dialect by trained 
interviewers, using a previously piloted questionnaire.  
A prior publication on the SPOCCS II study analyzed risk factors for HPV infection and CIN 
III or greater among the same women included in this present report [89].  However, relatively 
few reproductive variables were analyzed (parity and number of sexual partners) in this previous 
report. The present analysis explored comparisons of different histological categorizations, using 
alternate stratifications in order to investigate a broader range of reproductive factors affecting the 
risk of HPV infection, and progression to high-grade pre-cancer (CIN III). Our prior analyses 
indicated that risk factor profiles for CIN II are more similar to CIN I than CIN III [90], and thus 
the case group for high-grade disease was restricted to CIN III, rather than to the combined 
outcome of CIN II/CIN III.   
The major steps in cervical cancer carcinogenesis are infection with HPV, persistence of 
HPV infection over time, and progression from infection to pre-cancer and invasion [26]. The p53 
protein, a tumor suppressor gene, prevents cell growth in the presence of cell damage. HPV 
oncogenic proteins E6 and E7 can both inhibit p53, thus leading to carcinogenesis. Initial HPV 
infections are common, with most women developing  immunity against HPV within two years 
with cessation of viral replication [27]. Some women however develop persistent infections, and 
thus have a higher risk of progression to higher grades of CIN. Currently, a two-tiered system 
describes the morphologic classification of non-invasive HPV-associated cervical lesions: CIN I 
(low-grade lesion) a non-neoplastic lesion with a low likelihood for progression and CIN II/CIN 
III high-grade lesions with a greater likelihood for progression to invasive cervical cancer [27]. 
Low-grade lesions may be caused by low or high-risk HPV infections [27]. In contrast, high-
grade lesions are almost always associated with high-risk HPV types, are characteristic of E6 and 
E7 expression, and often show integration of the HPV viral genome into the host cell [28]. It is 
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likely that the uncontrolled E6/E7 expression is a phenomenon that distinguishes the process of 
cell transformation from a productive viral infection [2]. E6/E7 mRNA has been found to be 
associated with high-grade cervical pre-cancer and cancer [29], although further prospective 
studies are indicated. 
Our analyses suggest that reproductive risk factors, notably pregnancy history, likely play a 
more important role in the progression to CIN III than in susceptibility to HPV infection, which 
appear largely dependent upon sexual behavioral risk factors. Our results that a woman’s number 
of pregnancies may modulate the risk of progression of CIN II or less to CIN III are consistent 
with previous reports [3, 87, 91]. Our findings add evidence to the existing body of evidence that 
pregnancies may affect a women’s risk of high-grade pre-cancer. A recent pooled analysis of 
16,563 women with cervical cancer and 33,542 controls from 25 epidemiologic studies found a 
direct relationship between number of full term pregnancies and CIN III or cancer. Relative risks 
were found to increase with each additional pregnancy [10].  
Observed associations between CIN I/HPV positives and number of sexual partners are also 
consistent with other studies [89, 92-94]. In a pooled analysis of the IARC HPV prevalence 
studies, a significant trend of decreasing HPV positivity was seen with increasing age at first 
intercourse. HPV infection risk, however, was not significantly increased for women initiating 
intercourse at age 15 compared to women initiating at age 24 [95]. Our multivariate results 
suggested that abortion history was not a risk factor for HPV,  in constrast with two other studies 
that found a lower risk of HPV among women with a reported history of abortions from Thailand 
[19] and Vietnam [92]. Based on our data we found no evidence that women with more 
pregnancies were are a greater risk for HPV infection. 
Pregnancy may increase the risk of cervical cancer due to the maintainance of the 
transformation zone on the ectocervical region during the full period of the pregnancy, thus 
increasing a woman’s risk of HPV infection. The maintaince of the transformation zone is due to 
circulating estrogen and progestin levels that become elevated during pregnancy. The number of 
 4545 
45 
metaplastic cells in the transformation zone have been shown to increase during pregnancy [5]; it 
is during this immature phase of development that cells are most susceptible to HPV infection 
[35]. In a woman who has experienced multiple pregnancies, the metaplastic transformation zone 
will have repeatedly been exposed to carcinogenetic agents including HPV infection. Repeated 
exposure experienced over multiple pregnancies may intensify the actions of carcinogenic 
infectious agents causing increased risk for cervical cancer [41].  
Research data suggest  a role of endogenous hormones in cervical carcinogenesis in both 
epidemiological [8] and laboratory studies [42-46]. Hormones during pregnancy may also favor, 
or accelerate cervical carcinogenesis, with a mechanism similar to that for oral contraceptives 
[47, 48]. The data consistently points to oral contraceptives promoting process of cervical 
carcinogenesis rather than having a role in facilitation of HPV acquisition or persistence [49].  
However, a case-control study found no evidence that plasma levels of sex hormones (estrogen 
and progesterone) are associated with an increased risk of cervical cancer in HPV infected 
women [40]. 
Pregnancy could also act as a promoter, rather than an initiator in the process of cervical 
carcinogenesis, a hypothesis supported by our data. Papillomavirus replication depends on 
elevated levels of transcription viral genes, which in turn can be activated in response to 
progesterone [96-98]. Alternatively, the mechanism may not be related to pregnancy per se, but to 
cervical inflammation and trauma during delivery. In the IARC multicenter study, women who 
reported cesarean but not vaginal deliveries had a lower risk of cervical cancer [OR=0.98 (0.36, 
2.7)] when compared to nulliparous women. Further, parous women who reported only cesarean 
deliveries had a lower risk of cervical cancer compared with women who reported vaginal 
deliveries only, but the 95% CI of study effect estimates were broad (0.1-1.1) due to the rarity of 
cesarean delivery in the study [5]. Pregnancy-induced immunosuppression may also favor the 
infection or aid in the oncogenic properties of HPV [9]. Our data would suggest that pregnancies 
play a role in the progression to CIN III, and do not increase a woman’s risk of HPV infection. 
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Our observed association between CIN III and intercourse within four months of birth is 
novel. A similar variable was tested among 759 women with invasive cancer and 1,430 controls 
in a case-control study in Latin America, where no association was found [7]. To gain 
understanding of this association, we conducted analyses to identify predictors of intercourse 
within four months of birth. Older age was highly associated with having intercourse within four 
months of childbirth and having more than one lifetime sexual partner was protective. However 
the association of earlier return to intercourse remained even after adjustment for age and number 
of sexual partners. Women who had a high proportion of pregnancies resulting in live births 
(excluding abortions) were more likely to engage in intercourse soon after childbirth, but for the 
variable that included abortions in its calculation, having medium to high success made these 
women less likely to engage in intercourse soon after childbirth. Although the possible 
association between intercourse within four months of delivery and CIN III is intriguing, 
additional work is needed to clarify both the actual timing of intercourse and the potential 
biological mechanisms.  Intercourse within 6-8 weeks of delivery would occur in a time of 
significant inflammatory response and tissue remodeling; exposure to semen or additional 
microtrauma from intercourse could exacerbate processes which facilitate progression [99]. 
Conversely, assuming that the majority of women in Shanxi province breast-feed, hormonal 
changes related to lactation may affect immune response. In this study approximately 30% of 
women had resumed intercourse within four months of childbirth. This is substantially lower than 
was reported for women in an urban population in Zibo, China where 93% of women had 
resumed sexual intercourse at four months postpartum [100].  
Similarly, it is unclear to what extent the association between number of pregnancies and CIN 
III is due to some factor related to the pregnancy (such as effects of pregnancy hormones on 
immune function or physical properties of the cervix affecting progression risk), or some 
independent host factor associated with both risk of HPV progression and the ability to achieve 
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pregnancy.  If the former, we would have expected both the number of pregnancies and number 
of live births to be associated with CIN III risk.  
While population-based, our findings from two rural counties in Shanxi province cannot be 
considered representative of the very diverse Chinese population. The cross-sectional nature of 
the data limits our ability to draw causal links and estimate the timing of each risk factor’s 
contribution to cervical carcinogenesis. Cohort studies allow for observation of the timing of 
oncogenic HPV infection, and progression from oncogenic HPV infection to CIN III. Cross-
sectional data only provide measurements at a single time point and therefore, we utilized data 
within histologic grades as a proxy for progression. Reliance on self-reported data may have led 
to under- or over-reporting of reproductive variables. The quality of self reported data are often 
difficult to verify, but due to the one child policy in China there has been strong incentive to have 
reliable reproductive information and to report pregnancies, abortions, live and still births to the 
government [78]. While initially surprised to see the range in numbers of pregnancies (0-10) and 
live births (0-10), these numbers were validated against means for the province (typical for a rural 
environment) and fall within normal limits.  
In conclusion, our findings add to the accumulating evidence that reproductive co-factors 
play an important role in the progression of persistent high-risk HPV infection to CIN III, 
whereas sexual behavior may be a more important risk factor for HPV acquisition. Prospective 
data is needed to further untangle the effects of these variables. Determining the stage or stages of 
carcinogenesis affected is an important next step in understanding the natural history of the HPV 
and cervical cancer relationship. 
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Table 8. Selected Characteristics of Study Participants among 2,055 HPV DNA Positive and 6,657 HPV Negative Women 
 in the SPOCCS II Study, Stratified by Histological Diagnosis 
 
Characteristic 
HPV Negative, 
Normal 
Cytology 
N=6,657 
HPV Positive 
Normal 
Cytology 
N=1,405 
CIN I 
N=299 
CIN II 
N=167 
CIN III 
N=184 
Median Age (range), years 
41  
(35-50) 
40 
 (35-50) 
40  
(35-50) 
41  
(35-50) 
42  
(35-50) 
Percent Married (%) 99 98 97 96 99 
Median Age at First Intercourse (Range), years 
20  
(15-31) 
20  
(15-33) 
20  
(15-28) 
20  
(16-26) 
20  
(16-24) 
Percent Having Intercourse Within 4 Months of Childbirth 
(%) 34 31 37 28 44 
Median Number Lifetime Sexual Partners (range) 1 (1-27) 1 (1-10) 1 (1-8) 1 (1-10) 1 (1-12) 
Median Number of Pregnancies (range) 3 (0-13) 3 (0-9) 3 (0-8) 3 (0-10) 3 (0-8) 
Median Number of Live Births (range) 2 (0-8) 2 (0-7) 2 (0-5) 2 (0-5) 2 (0-5) 
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Table 9. Crude and Age-Adjusted Odds Ratios for Selected Reproductive Characteristics among 2,055 HPV DNA  
Positive Women and 6,657 HPV Negative Women in the SPOCCS II Study.  
 
 
Characteristic 
 
CIN III vs ≤CIN II 
 
Cases/Control   OR (95% CI)1     OR (95% CI)2 
 
CIN I or HPV positive Normal Cytology 
vs. CIN negative/HPV negative 
Cases/Control   OR (95% CI)1      OR (95% CI)2 
Age (years) 
    35-39 
    40-44 
    45-50 
 
62/824 
52/598 
70/449 
 
1.0 
1.2 (0.79, 1.7) 
2.1 (1.4, 3.0) 
 
1.0 
1.2 (0.79, 1.7) 
2.1 (1.4, 3.0) 
 
762/2940 
543/2055 
339/1662 
 
1.0 
1.0 (0.90, 1.2) 
0.93 (0.81, 1.1) 
 
1.0 
1.0 (0.90, 1.2) 
0.93 (0.81, 1.1) 
Age at First Intercourse (years) 
    ≥ 21 
   19-20    
   12-18 
 
67/827 
41/343 
76/701 
 
1.0 
1.5 (0.98,2.2) 
1.3 (0.95, 1.9) 
 
1.0 
1.1 (0.74, 1.8) 
1.3 (0.89, 1.8) 
 
756/3108 
312/1086 
636/2462 
 
1.0 
1.2 (1.0, 1.4) 
1.1 (0.94, 1.2) 
 
1.0 
1.3 (1.1, 1.5) 
1.1 (0.96, 1.2) 
Lifetime Sexual Partners 
    1 
    2 
    ≥ 3 
 
122/1217 
26/365 
36/289 
 
1.0 
0.71 (0.46, 1.1) 
1.2 (0.84, 1.8) 
 
1.0 
0.70 (0.45, 1.1) 
1.2 (0.80, 1.8) 
 
1110/4875 
328/4875 
266/787 
 
1.0 
1.4 (1.3, 1.7) 
1.5 (1.3, 1.7) 
 
1.0 
1.5 (1.3, 1.7) 
1.5 (1.3, 1.8) 
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Reported # Pregnancies 
    0-2 
    ≥ 3 
 
50/688 
134/1183 
 
1.0 
1.6 (1.1, 2.2) 
 
1.0 
1.5 (1.0, 2.1) 
 
624/2536 
1080/4121 
 
1.0 
1.1 (0.95, 1.2) 
 
1.0 
1.1 (0.96, 1.2) 
Reported # Live Births 
    0-2 
    ≥ 3 
 
126/1265 
57/593 
 
1.0 
0.97 (0.70, 1.3) 
 
1.0 
0.81 (0.58, 1.1) 
 
1157/4626 
535/1973 
 
1.0 
1.1 (0.97, 1.2) 
 
1.0 
1.1 (0.99, 1.2) 
Intercourse Within Four Months 
of Childbirth         
    No 
    Yes 
 
 
103/1274 
80/584 
 
 
1.0 
1.7 (1.2, 2.3) 
 
 
1.0 
1.7 (1.2, 2.3) 
 
 
1154/4404 
538/2195 
 
 
1.0 
0.94 (0.83, 1.0) 
 
 
1.0 
0.94 (0.83, 1.0) 
Reported # Abortions  
    None 
    1  
    ≥ 2 
 
113/1177 
41/452 
29/229 
 
1.0 
0.94 (0.65, 1.4) 
1.3 (0.86, 2.0) 
 
1.0 
0.99 (0.68, 1.4) 
1.5 (0.94, 2.3) 
 
1066/4293 
415/1431 
211/875 
 
1.0 
1.2 (1.0, 1.3) 
0.97 (0.82, 1.1) 
 
1.0 
1.2 (1.0, 1.3) 
0.96 (0.82, 1.3) 
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Current Contraception Use  
    Female Sterilization 
    Intrauterine Device 
    Oral Contraceptives 
    Condoms 
    None 
 
158/1448 
15/293 
2/21 
0/8 
9/99 
 
1.0 
0.47 0(.27, 0.81) 
0.87 (0.20, 3.8) 
- 
0.83 (0.41, 1.7) 
 
1.0 
0.52 (0.30, 0.91) 
1.1 (0.25, 4.7) 
- 
0.86 (0.42, 1.7) 
 
1316/5295 
274/947 
17/92 
7/17 
88/305 
 
1.0 
1.2 (1.0, 1.3) 
0.74 (0.44, 1.3) 
1.1 (0.69, 4.0) 
1.2 (0.91, 1.5) 
 
1.0 
1.2 (1.0, 1.3) 
0.74 (0.44, 1.2) 
1.6 (0.68, 3.9) 
1.2 (0.91, 1.5) 
1 Crude OR and 95% CI.  
 
2 Age-Adjusted OR and 95% CI; Numbers rounded to 1.0.
 
Notes: Controls for the comparison with CIN 1 are HPV negative women with normal cytology. Age adjustment was by categorical years 
as follows: 35-39, 40-44, 45-50. 
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Table 10. Multivariate Odds Rations for Intercourse within Four  
Months of Childbirth among 8,062 Control Women in the SPOCCS II Study. 
 
Characteristic Negative Cytology 
OR (95% CI) 
Age (years) 
   35-39 
   40-44 
   45-50 
 
1.0 
1.2 (1.0, 1.3) 
1.6 (1.4, 1.8)  
Lifetime Sexual Partners 
    1 
    2 
    ≥ 3 
 
1.0 
0.5 (.41, .55) 
0.3 (.26, 38)  
Reported # of Pregnancies 
    0-2 
    ≥3 
 
1.0 
0.5 (.41, .53)  
Reported # of Abortions 
   None 
   1  
   ≥ 2 
 
1.0 
2.1(1.9, 2.5) 
3.5 (3.0, 4.2)  
Current Form of Contraception 
    Female Sterilization 
    IUD 
    Oral Contraceptive 
    Condoms 
    None 
 
1.0 
3.3 (2.9, 3.8) 
3.4 (2.2, 5.1) 
0.8 (.31, 2.2) 
2.7 (2.1, 3.3)  
Note: Age adjustment was by categorical years as follows: 35-39, 40-44, 45-50. 
 5353 
53 
53 
Figure 4: Causal Diagram for the Relationship between HPV infection, Reproductive Factors and the risk of CIN III. 
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Figure 5. Multivariate OR and 95% CI for Selected Reproductive Risk Factors for CIN III vs. ≤ 
CIN II among women in the SPOCCS II trial.  
 
 
1 Variable in the model was intercourse within four months of childbirth (yes/no) 
 
2 Variable in the model was IUD vs. female sterilization 
 
 
CIN III vs. ≤ CIN II 
Age 40-44 vs. 35-39 
Age 45-50 vs. 35-39 
Pregnancies ≥3 vs. 0-2 
Intercourse within 4 months of childbirth1
IUD for birth2 
Variables 
1.10 (0.75, 1.61)
1.80 (1.22, 2.65)
1.60 (1.13, 2.26)
2.00 (1.46, 2.73)
0.42 (0.24, 0.73)
Odds Ratio (95% CI) 
  1.25 .5 2 4 8
Odds Ratio (log scale)
 55 
55 
Figure 6. Multivariate OR and 95% CI for Selected Reproductive Risk Factors for  
CIN I/HPV positive vs. HPV negative among women in the SPOCCS II trial. 
 
 
1Variable in the model was age at first intercourse of 19-20 versus ≥ 21 
 
2Variable in the model was age at first intercourse of 12-18 versus ≥ 21 
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V. RESULTS 
 
 
CHAPTER V 
 
CONCLUSIONS 
 
A. Summary 
Results from this study add to the evidence that CIN II may be more similar to CIN I than to 
CIN III, as shown through risk factor profiles. Reproductive risk factors may play an important 
role in the progression from an HPV lesion to CIN III, while sexual behavior is important for the 
acquisition of the initial HPV infection. Potential misclassification of CIN II lesions may be 
leading to over-treatment of CIN lesions that would regress over time if left alone. Reproductive 
risk factors may have a role in the progression of HPV to high-grade cervical pre-cancer. It is 
biologically plausible that elevated levels of hormones during pregnancy and immediately 
postpartum may act as promoters in cervical carcinogenesis, aiding in the progression of cervical 
disease. Results from this study provide impetus to further investigate the role that some 
reproductive cofactors may have as promoters.      
 
B. Study Limitations 
The reliability of the self-reported data on current and previous sexual behavior, as in any 
study, may be compromised if women were reluctant to disclose sexual behavioral information.  
Due to the one child policy in China there has been strong incentive to have reliable reproductive 
information and to report pregnancies, abortions, live and still births to the government. Ranges 
of pregnancies and live births were compared to means for the province (typical for a rural 
environment).  Female interviewers were used who received training in approaching study 
participants in a culturally acceptable way and assuring them that all responses would remain 
confidential. 
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Women who test positive for HPV today may have been infected in the past and past 
infection may have played a role in their current health state. Although persistent HPV infections 
are pointed to as the cause of cervical cancer, the role of past infections is unclear. 
In general, it is a limitation to use cross-sectional data when looking at an infection that is 
transient, as is HPV. In this specific situation the majority of women are married (98%), the level 
of reported extra-marital affairs is low and all women are over the age of 35, leading us to believe 
that the incidence of new infections is low and that the majority of these infections in fact 
represent the persistent infections that occasionally progress to cervical cancer.  
 
C. Study Strengths 
Data from the Shanxi Province Cervical Cancer Screening study II (SPOCCSII) was utilized 
for several reasons. The dataset contains 8,497 women, with histologic confirmation of disease 
for women who experienced a positive HPV test and/or positive cytology. The extensive 
histologic confirmation of disease eliminated some issues of misclassification and verification 
bias. These data provided a fairly homogeneous population with respect to risk factors like age, 
smoking status and marital status while at the same time being diverse enough to provide 
variation on other important cofactors (i.e. pregnancies). This offered an opportunity to look at 
women who do not differ in some of the major areas that affect cervical status, such as smoking.  
Due to the concern regarding the heterogeneity of CIN II lesions, biopsies from SPOCC I (a 
SPOCCS II precursor ) were reviewed for agreement, the proportion of biopsies said to be 
misclassified were applied to the results of this study. On review 92% of CIN II remained CIN II, 
2.4% was reclassified as CIN I, 4.8% as normal histology and 1.2% as CIN III. When odds ratios 
and 95% confidence intervals were recalculated for higher gravidity, no change in the magnitude 
of the effect was observed, suggesting that misclassification in this study was negligible. 
 58 
D. Future Directions 
The majority if not all cervical cancers are attributable to HPV infection [101-103]. 
Histological classifications along the path from HPV infection to CIN III or cancer are under 
review. The current challenges are: to determine if CIN II has low progression potential, as is the 
case with CIN I, or if it is more similar to CIN III and to unravel the potential roles of cofactors in 
the acquisition of HPV infection, development of persistent infection, and the rare progression 
from HPV infection to cervical cancer.  
While the results from this study cannot answer the questions of cofactor roles in HPV 
infection, persistence, and progression, we encourage those with prospective data to complete 
case-case analysis to identify risk factor differences among histological grades, and to follow up 
women with CIN II to see if they progress more similarly to CIN III or to CIN I.  
 59 
APPENDICES 
 
A.  Variables Available for Analysis with their Original Coding in the SPOCCS II Dataset 
 
B.  Questionnaire from the SPOCCS II study 
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Appendix A.  Variables Available for Analysis with their Original Coding  
in the SPOCCS II Dataset 
Variables Code 
Subject age Numeric Age 
Marriage status 
1=Married; 2= Divorced;  
3= Widow; 4= Single 
Education 
 
1=No formal schooling; 
2=Primary school;  
3=Middle school;  
4=Over senior high school 
Bathing location 
1=Bathing in public house;  
0=Bathing at home 
Current smoke 1=Yes; 2=No 
Drink alcoholic beverage 1=Yes; 2=No 
Age of first menstrual period Numeric Age 
Days between menstrual periods 0=Missing 
Days for each period 0=Missing 
Menopausal status 
1=Menopause;2=No menopause;  
3=Premenopause; 4=Missing 
Age at menopause 
Numeric Age 
0=Missing 
Husband multiple sexual partners 1=Yes; 0=No 
Pregnancies number Numeric 
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Live birth number Numeric 
Stillbirth number Numeric 
Miscarriage number Numeric 
Abortion number Numeric 
Births delivered in hospital Numeric 
Births delivered at home Numeric 
At what month had sexual intercourse during the 
pregnancy Numeric 
At what month had sexual intercourse after 
delivery Numeric 
Age at first sexual intercourse 
Numeric Age 
0=Missing 
Subject multiple sexual partners 1=Yes; 2=No 
How many sexual partners in your life Numeric 
Sexual frequency during the youth period Numeric 
Sexual frequency during the mid-age period Numeric 
Genital wash before sexual intercourse 
1 = Always;  2 = Sometimes;  
3 = Rarely or Never 
Genital wash after sexual intercourse 
1 = Always;  2 = Sometimes;   
3 = Rarely or Never 
Birth control methods 
1= IUD; 2= Birth control pill; 
 3=Condom or rubber;  
4=Operation-female sterilization;  
 5=No; 9=Missing 
Ever diagnosis of Hepatitis 1=Yes; 2=No; 9=Missing 
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Age at first diagnosis for hepatitis 
Numeric Age 
0=Missing 
Ever diagnosis of Cancer 1=Yes; 2=No; 9=Missing 
Age at first diagnosis for cancer Numeric Age 
0=Missing 
Ever diagnosis of Cervical inflammation 1=Yes; 2=No; 9=Missing 
Diagnosis times for cervical inflammation Numeric 
Ever diagnosis of Urinary tract infection 1=Yes; 2=No; 9=Missing 
Diagnosis times for urinary tract infection Numeric 
Ever diagnosis of Gonorrhea 1=Yes; 2=No; 9=Missing 
Diagnosis times for gonorrhea Numeric 
Ever diagnosis of Syphilis 1=Yes; 2=No; 9=Missing 
Diagnosis times for syphilis Numeric 
Ever diagnosis of Condyloma 1=Yes; 2=No; 9=Missing 
Diagnosis times for condyloma Numeric 
Ever diagnosis of Genital herpes 1=Yes; 2=No; 9=Missing 
Diagnosis times for genital herpes Numeric 
Ever diagnosis of Genital ulcers              1=Yes; 2=No; 9=Missing 
Diagnosis times for genital ulcers Numeric 
Ever diagnosis of Vagina Trichomoniasis 1=Yes; 2=No; 9=Missing 
Diagnosis times for vagina trichomoniasis Numeric 
Ever diagnosis of Mycosis 1=Yes; 2=No; 9=Missing 
Diagnosis times for mycosis Numeric 
Ever diagnosis of Other Sexual Transferred 
Disease 1=Yes; 2=No; 9=Missing 
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Diagnosis times for other sexual transferred 
disease Numeric 
Vaginal discharge 1=Yes; 2=No; 9=Missing 
Cancer family 1=Yes; 2=No; 9=Missing 
Pathology grade for cervical intraepithelial 
lesion 
1=SCC; 2=CIN III; 3=CIN II;  
4=CIN I; 5=Normal 
HPV self test result 1=POS; 2=NEG; 9=Missing 
HPV direct test result 1=POS; 2=NEG 
County code 1=Xiangyuan; 2=Yangcheng 
Cervical cancer family history 1=Yes; 0=No 
Screening season 1=Spring; 2=Summer; 3=Winter 
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Appendix B. Questionnaire from the SPOCCS II study 
 
 
Subject Name:  __________________           Subject ID Number: |__|__|__|__|__|-
|__|__|__|__| 
Subject Social Security Number:       
|__|__|__|__|__|__|__|__|__|__|__|__|__|__|__| 
Interviewer Name: _______________                        Interviewer number:          |__|__| 
Time of Interview Began: |__|__| : |__|__|  
Subject Address:                                                                                                        
Address: _________ County __________Commune  ________Village;    
Zip Code  |_|_|_|_|_|_| 
Phone:   ________________;    Partner Name: ________ 
 
1. Eligibility of Subject: 
(1)  35-45 year old woman in local; 
    (2)  Not being pregnant or planning to pregnancy; 
    (3)  No prior hysterectomy history;  
    (4)  No prior pelvic radiation history;  
    (5)  Not a deaf or dumb. 
 
2. Introduction before interview: 
    Hello, my name is (XX). I am working on a research study for CAMS cancer institute and 
associated departments of Shan Xi province. I am here to speak with you about a number of topics 
associated with health, such as your medical history, birth control practices, your pregnancy history, 
your family history, smoking and so on. Perhaps some contents may interfere with your privacy. 
    We ask you these questions for the requirements of cancer study. All of information will be 
collected and analyzed obeying strict rules for keeping secret for your privacy. Only grouped data 
will be concluded for this study, and you will never be able to be identified from it. Thank you for 
cooperation. 
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A. Section I     General Information 
 
1.1.  How old are you now? |__|__| 
1.2.  Marriage condition: 
  0 = Unmarried; 1 = Married;   2 = Divorce;    3 = Widow                                |__| 
1.3. Do you consider yourself to be han, hui or another ethnic group? 
  1 = Han;                 2 = Hui;            3= Other, specify__________                           |__| 
1.4. What is the highest grade or level of schooling you completed? 
   0 = No formal schooling;   1 = Primary school;  
   2 = Junior high school     3=Over senior high school         
                     |__| 
1.5.  What is your birthplace?   _______________ Province___________county/City 
1.6. Do you have sisters aged 30-50? 
                          1=Yes (continue)                     2= No (skip to 1.8 )                                        
             |__| 
1.7 Have they taken part in the study? 
                            1=Yes (Names_____________________________________)           
  2=No        
                   |__| 
1.8.  When you bathe, do you use? 
   1 = A shower;    2 = A bath tub in your home; 
   3 = Public bathhouse;   4 = Other, specify__________             
                     |__| 
1.9.  What is your chief source of drinking water? 
   1 = Well, Pond / lake;  2 = Spring, River;  3 = Tap water            
                     |__| 
1.10.  Have you been smoking for six months or more? 
   1 = Yes (continue);  2 = No (skip to 1.17 )       
                           |__| 
1.11.  At what age did you start smoking cigarettes regularly for six or more months?      |__|__| 
1.12. When smoking, do you inhale into the chest?  
   1 = Yes;     2 = No                              
                    |__| 
1.13. ( During periods when you smoked ) What do/did you usually smoke ?  
1 = Cigarette (continue);  2 = Tobacco(skip to 1.15);    3 = Both            
                      |__| 
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1.14. ( During periods when you smoked ) do/did you usually smoke filtered or unfiltered 
cigarettes? 
 1 = Filtered cigarette 2 = Unfiltered cigarette;  3 = Both            |__| 
1.15. ( During periods when you smoked ), how many tobacco product ( per day / month 
) do/did you smoke?     a. Tobacco |__|__|  liang / month 
           b. Cigarettes    |__|__| cigarettes/day 
1.16. Do you smoke now? 
   1 = Yes;     2 = No           
                   |__| 
1.17. At what age did you stop smoking regularly?    Age  |__|__| 
1.18. How many years have you smoked?                             YR  |__|__| 
1.19.   Do you drink alcoholic beverages?   
   1 = Never   2 = Sometimes  3=Often                       
                                                                                                                                         |__| 
1.20. Tell me the kinds of alcoholic beverages that you drink? 
1 = Beer;    2 = Wine;  3 = Grain liquor;      
4 = Both beer and wine;  
5 = Both wine and grain liquor;    
6 = Both beer and grain liquor 
7 = All three types of beverages; 
8 = Another type of alcoholic drink, specify  |__| 
B. Section II    Menstrual History / Marriage and Birth 
2.1. At what age did you have your first menstrual period                                         Age  |__|__| 
2.2. At what age did your menstrual periods become established at regular intervals, that is, periods 
occurring at predictable intervals?               
                        Age  |__|__| 
 
2.3. On the average, over most of your adult life, how many days were there between menstrual 
periods? 
                              
                  |__|__| DY 
2.4. How many days of menstrual flow did you usually have each period?  (Note that any 
days of spotting should not be included.  Only days with a full flow should be counted.)  
 67 
 
                                                                                                                                |__|__|DY 
2.5. Have you had any changes in your menstrual cycle over the years? 
   1 = Yes(continue);  2 = No(skip to 2.7 )            
                   |__| 
2.6. If yes, at what age did your cycle change?             Age  |__|__| 
2.7. Have you had menopause? 
   1 = Yes(continue);  2 = No(skip to 2.9 )                        
                   |__| 
2.8. In which month and year did you have your last menstrual period?     
                                                                                                                    |__|__| - |__|__| YR - MO 
2.9. When you (are/were) having your menstrual period, what (do/did) you usually use to collect the 
blood? 
   1 = Sanitary napkin; 2 = Paper; 3 = Other, specify___________      
                   |__| 
2.10. How many times have you been married? ( Never married =0 )         |__|__| times 
2.11. Do you have a partner now? 
   1 = Yes;     2 = No             
                   |__| 
2.12. To your knowledge, did your husband / any of your husbands ever have sexual intercourse with 
another woman before or during your marriage? 
   1 = Yes;     2 = No             
                   |__| 
 
2.13. Including livebirths, stillbirths and abortions, how many times have you been pregnant?            
                   |__|__| 
2.14. Did you ever receive any medical treatment prescribed by a doctor to become pregnant?  
   1 = Yes ( explain why___________ );     2 = No                                        
                   |__| 
2.15. Was the outcome of your pregnancy? 
   a. Livebirth                 |__|__| times 
   b. Stillbirth                 |__|__| times 
   c. Miscarriage                |__|__| times 
   d. Abortion                 |__|__| times 
2.16. Do you have a child with a congenital defect such as a cleft lip or a heart defect and so on? 
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 a.. Livebirth  1 = Yes ( specify________________________ );   2 = No              |__| 
 b.. Stillbirth  1 = Yes ( specify________________________ );   2 = No              |__| 
2.17. How many births have you delivered in following places? 
   a. Hospital / Clinic             |__|__| birth 
   b. Home                |__|__| birth 
   c. Some other place, (specify_____________)       |__|__| birth 
2.18. Have you ever had a cesarean section? 
   1 = Yes;     2 = No          
 |__| 
2.19. (Besides the cesarean section) have you ever had any other problems during childbirth such as a  
         rupture or tear of any part  of the genital area? 
   1 = Yes;(continue)  2 = No(skip to 3.1);  3 = Don’t know (skip to 3.1)
  |__| 
2.20. During your most recent pregnancy, until what month did you have sexual intercourse?      
                                                                                                                                             |__|__|MO 
2.21. How long after the end of the most recent pregnancy did you begin having sexual intercourse 
again? 
                                                                                                                                             |__|__|MO 
C. Section III    History/Hygiene Habit 
    The next questions are about your sexual history and hygiene habits. We realize this is a personal 
topic, but it is very important to study. Please take the time to recall this information as accurately as 
possible. We will maintain secrecy for you. 
3.1. How old were you when you first had sexual intercourse with a man?         
 Age |__|__| 
      00 = Never had intercourse (skip to section IV)  
3.2 Did you have sexual intercourse with man besides your husband (sexual intercourse 
before marriage will be included) 
   1 = Yes;     2 = No          
                  |__| 
3.3. Through your life, how many men have you had sexual intercourse with?                
                  |__|__| 
3.4. On the average, how long did you have a sexual intercourse? Answer in the easiest 
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way. If the frequency is not constant in a period, mark the largest frequency. ( Never 
happened, please fill 0 ) 
1. Youth Period (~29)         
         |__|__| times / month 
2. Middle-Age Period (30~49)        
         |__|__| times / month 
3.5.  Do you usually wash genital area before sexual intercourse? 
   1 = Always;  2 = Sometimes;  3 = Rarely or Never     
                  |__| 
3.6.  Do you usually wash genital area after sexual intercourse? 
   1 = Always;  2 = Sometimes;  3 = Rarely or Never     
                  |__| 
D. Section IV    Contraceptive History 
        I am interested in all the methods of birth control or family planning you have used since you 
had sexual active. 
4.1. Now, I’d like to read to you a list of birth control methods. Please tell me if you and your partner 
have ever used any of these methods? 
   1 = IUD;   2 = Birth control pill;  3 = Condom or rubber 
   4 = Operation-female sterilization;   5 = No (skip to section V after 4.2)              
                  |__| 
4.2. What is the major reason you have never used a method of birth control or family planning? 
   1 = Never know about it;   2 = Partners is not fertile 
   3 = Subjects is not fertile or has trouble becoming pregnant; 4 = Other reasons  
                  |__| 
4.3. How old were you when you last used a method of birth control?      |__|__| 
4.4. I’d now like to find out which pills you were using. Please tell me the name of the pill you often 
used? 
  1st pill:   Name of pill_________     |__|__|YR         
  2nd pill:  Name of pill_________   |__|__|YR 
 4.5. If you have used an IUD, how long have you used it?      _____________ 
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E. Section V    Medical History 
5.1. Have you been ever diagnosed with following disease (condition) before? 
                       1 = Yes / 2 = No         How old were you when you first had? 
   a: High blood pressure      |__|      |__|__| age 
   b: Diabetes                        |__|      |__|__| age 
   c: Gall bladder disease      |__|      |__|__| age 
   d: Thyroid disease             |__|      |__|__| age 
   e: Tuberculosis                 |__|      |__|__| age 
   f: Hepatitis                        |__|      |__|__| age 
   g: cancer                           |__|      |__|__| age 
 
 
5.2. Have you been ever diagnosed with following disease (condition) before? 
          1 = Yes / 2 = No      How many times have you 
suffered it? 
  a. Cervix erosion or chronic inflammation, polyp  |__|      |__|__| times 
  b. Urinary tract infection        |__|      |__|__| times 
  c. Gonorrhea                       |__|      |__|__| times 
  d. Syphilis                           |__|      |__|__| times 
  e. Condyloma           |__|      |__|__| times 
  f. Genital herpes                   |__|      |__|__| times 
  g. Genital ulcers                    |__|      |__|__| times 
  h. Vagina Trichomoniasis       |__|      |__|__| times 
  i. Mycosis                 |__|      |__|__| times 
  j. Other Sexual Transferred Disease     |__|      |__|__| times 
 
5.3. Did you have a vaginal discharge or vaginal irritation? 
   1 = Yes  (What color was the discharge? _______);  2 = No     
                  |__|__| 
5.4. Did you ever see a doctor or other health professional about genital condition such as a vaginal 
discharge or vaginal irritation?  
   1 = Yes(continue);   2 = No(skip to section 5.8)        
                   |__| 
5.5. Have you been received some treatment? 
   1 = Yes(continue);   2 = No(skip to section 5.8)        
                   |__| 
5.6. What type of treatment have you received? 
   1 = electrotherapy   2 = refrigeration 
   3 = laser      4 = other treatment        
                   |__| 
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5.7. Are there someone in your family have suffered some cancer? 
   1 = Yes(continue);   2 = No(skip to section VI)        
                   |__| 
5.8. Who are they suffered with some cancer? 
     Relative to you      Name          Alive     Cancer Name / ICD-10 code          Address 
  (1) _____________   _____________     |__|    ________________ / |__|__|__|__|  ________________________ 
  (2) _____________   _____________     |__|    ________________ / |__|__|__|__|  ________________________ 
  (3) _____________   _____________     |__|    ________________ / |__|__|__|__|  ________________________ 
  （Note：Alive:1=Yes  2=No 
       If there are more than two person in her family, including 
subject herself, have suffered with following cancer, it is 
necessary to fill in the Questionnaire for Family Study. These 
cancer types are cervix cancer, malignant neoplasm of body of 
uterus, malignant neoplasm of ovary and other uterine adnexa, 
malignant neoplasm of placenta, esophageal cancer, breast 
cancer and carcinoma in situ of breast and cervix. ) 
 
1. Section VI      Records for interviewer 
6.1 If you got support when you ask the questions?  
1 = best;  2 = good;  3 = not bad;   4 = bad    
           |__| 
6.2 Can the interview subject answer your questions accurately? 
1 = Very Accurate; 2 = Accurate;  3 = not accurate for some parts; 
4 = Not accurate; 5 = Uncertain         
           |__| 
6.3 Assessment for whole interview quality 
1 = good;  2 = general;  3 = doubt;  4 = not satisfy   
           |__| 
6.4 Which sections are not reliable? Please circle the section number you selected.   
               1 ,     2 ,      3 ,     4 ,     5                   
6.5 name of interview subject         
 1 = subject herself      2 = other person    
           |__| 
6.6 Time of Interview Ended:  |__|__| : |__|__| 
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